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The World Health Organization (WHO) has a long-standing interest in xenotransplantation, 
which started with the publication of the “WHO Guidance on Xenogeneic Infection/Disease 
Surveillance and Response: A strategy for International Cooperation and Coordination” in 
2001 [1]. A major milestone being resolution WHA57.18 of the 57th World Health Assembly 
in 2004, urging member states, amongst others, to perform xenogeneic transplantation only 
“when effective national regulatory control and surveillance mechanisms overseen by 
national health authorities are in place” [2]. This resolution followed a position report 
published by the International Xenotransplantation Association (IXA) on ethical aspects 
pointing to the requirements of adequate preclinical data, proper oversight by competent 
authorities, and approval by institutional bodies overseeing the ethical conduct of human 
research and animal welfare [3].  The WHO resolution was followed by global consultations, 
the first one being a Xenotransplantation Advisory Consultation in Geneva in 2005 [4], which 
was followed by the first WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials, published as the Changsha communiqué in 2008 [5]. In 
2011 the Second WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials was held in Geneva focusing on xenotransplantation-
associated infectious risk [6,7].  
 
The major progress in xenotransplantation research and development over the past few 
years motivated the necessity for an update of these WHO documents, in particular the 
Principles and Recommendations to various parties including WHO itself, member states, 
and investigators. Professor Wayne J Hawthorne from Sydney, Australia took the initiative to 
mark the 10-year anniversary of the Changsha Communiqué with the organization of the 
third WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical 
Trials. In collaboration between WHO, IXA and the Third Xiangya Hospital of the Central 
South University, Changsha, Hunan, China, this meeting was held in Changsha, December 
12-14, 2018. 
 
The Central South University and The Transplantation Society served as host, with Dr 
Guogang Zhang, President of the Third Xiangya Hospital chairing the opening of the 
meeting. The WHO was the convenor and secretariat being formally represented by 
Professor José Ramón Nuñez. The program committee included Professor Wayne J 
Hawthorne (Program Chairman, Sydney, Australia), Professor Peter Cowan (Past President 
of IXA, Melbourne, Australia) and Professor Léo Bühler (President IXA, Geneva, 
Switzerland): Professor Wei Wang and Professor Shounan Yi (Central South University, 
Changsha) served on the local organizing committee.  
 
There were 36 invited participants from many countries around the world including 
participants from Asia. A number of dignitaries also attended and provided speeches along 
with 20 invited international experts who presented updates in the field in two sessions 
during the first part of the meeting. This was followed by a session on the regulatory 
environment and the role of WHO and IXA in the regulation of xenotransplantation. 
Thereafter, the Principles and Recommendations of the Changsha Communiqué were 
reviewed and discussed in separate sessions by six working parties: 1) xenozoonosis; 2) 
regulatory; 3) biorepository; 4) transgenic pig facilities; 5) biomaterials and encapsulation; 
and 6) immunosuppression and tolerance induction. The Document from the Second Global 
Consultation (Geneva, 2011) was also included in these discussions. 
After feedback from the working parties, the final session focused on the revision of the WHO 
documents resulting in the formulation of the draft “Third WHO Global Consultation on 
Regulatory Requirements for Xenotransplantation Clinical Trials, The 2018 Changsha 
Communiqué”. This draft was submitted to WHO in February 2019 for approval and will then 
be posted on the websites of WHO, IXA and TTS, and published in Xenotransplantation. 
This report includes summaries of the various sessions, followed by the abstracts of invited 




Introduction and Opening Session 
 
The meeting was formally opened by Dr Guogang Zhang, President of the Third Xiangya 
Hospital, The Central South University, and Chairman of the Conference. Following his 
overview remarks and thanks to all participants from within China, Asia and the rest of the 
world he declared the meeting open.  
 
Dr José Ramón Nuñez then provided a comprehensive introduction to the meeting, outlining 
the ongoing support from the WHO. In his opening speech he stated that it was his great 
pleasure and honor to attend on behalf of the WHO. He thanked the Hunan Authorities for 
hosting and supporting this important meeting, and also the local and international organizers 
for their great job and effort to make it happen. For WHO, it is a priority as mandated by 
Members States to achieve Universal Health Coverage, and under this framework it is the 
responsibility of WHO to give the best evidence-based response to patient’s needs, from 
prevention to transplantation. Shortage of available organs unfortunately is a reality these 
days, and all efforts should be done to globally improve the quality of life and survival rates. 
Xenotransplantation is an open door while ethical and safety measures are followed. 
WHO thanked the Hunan Authorities for hosting and supporting this important meeting and 
also the local and international organizers forth meeting of WHO Executive Board in May 
2003. 
 
WHO’s interest in xenotransplantation started following discussions of access to 
transplantation and its safety and ethics during the 112th meeting of WHO's Executive Board 
in May 2003.  The World Health Assembly formalized its approach to Xenotransplantation in 
Resolution 57.18 on human organ and tissue transplantation adopted in May 2004: in its 
section related to xenotransplantation, the Director General of WHO was asked to take 
further action to improve communication and collaboration among health authorities in 
Member States; to collect data on xenotransplantation practices; to inform members of any 
xenogeneic infectious events; and to provide technical support in the field to Member States 
and report back to the Assembly. 
 
It was clear to WHO that xenotransplantation could bridge the gap between demand for, and 
supply of, human organs for transplantation. In April 2005 a meeting was arranged in 
response to the Resolution 57.18. During this meeting which took place in Geneva, 
xenotransplantation was defined as the transplantation, implantation, or infusion into a 
human recipient of living xenogeneic cells, tissues or organs, and human bodily fluids, cells, 
tissues or organs that have had ex vivo contact with these living xenogeneic materials. It was 
recognized that animals are a potential source of high quality, readily available live organs, 
tissues or cells for transplantation, but that three problems needed to be overcome, i.e., 
inadequate physiological function, rejection of the graft and the risk of transmitting a serious 
and/or novel infectious disease to the human recipient. But at the same time it was 
highlighted that successful xenotransplantation of organs could benefit many people. 
Xenotransplantation of tissues and cells also offers a potential treatment of diseases such as 
diabetes and some degenerative disorders. 
 
All of these concerns were clearly articulated in the Changsha Communiqué in November 
2008. Key recommendations were made to WHO, to Member States and to investigators and 
sponsors of clinical trials using xenotransplantation products. Dr Nuñez did not go into the 
very well-defined recommendations of the Changsha Communiqué that are well known, but it 
is clear that all xenotransplantation clinical trials and procedures need to be effectively 
regulated and there should be no xenotransplantation in the absence of effective regulation 
by the government of the country. The regulatory system should be transparent, must include 




In 2011 the Second WHO Global Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials was convened, and the importance of consensus between 
health authorities, experts and professionals on the various safety requirements for 
xenotransplantation clinical practice was pointed out as was discussed in Changsha. 
Participants at this meeting agreed that scientific, regulatory, and legal tools, applied in the 
context of rigorous adherence to the Changsha Communiqué's principles and 
recommendations, need to be adequate to protect public safety, and that the principles and 
guidance contained in the Communiqué remained valid. 
 
Since then, significant progress has been reported from preclinical xenotransplantation trials, 
mainly related to efficacy and infection risks, but better information on xenotransplantation 
trials and activities taking place in Member States is necessary to harmonize practices and 
facilitate collaborations.  
 
This meeting provided further guidance, insisting in particular on the need for transparency 
and external assessments of protocols, of their implementation and outcomes. Transparency 
in the development of national policies and procedures and in the conduct of any 
xenotransplantation trial, including (but not limited to) the trial design is essential to ensure 
harmonized practices and an acceptable level of safety. Considerable effort has already 
gone into improving the effectiveness and to minimizing the risks. As mandated by its 
Member States, WHO is strongly committed to working on concrete measures that can 
ensure that organ donation and transplantation are always carried out in a well-regulated, 
safe, and ethical way. 
 
IXA is putting these concrete measures in place, according to its mission “to promote 
xenotransplantation as a safe, ethical and effective therapeutic modality by: fostering the 
science of transplantation through promotion of ethical clinical and preclinical research; 
educating health care providers and society in an interactive public debate; and guiding the 
development of scientifically public policy in the field considering different social, ethical and 
legal frameworks. Dr Nuñez assured full support from WHO. The present Global 
Consultation was designed to discuss planned or ongoing xenotransplantation clinical 
activities and provide a framework for exchanges identifying needs for advice and 
collaborations.  
It was seen as a great opportunity to review, discuss and update if needed, this important 
communique and to set the pathway forward based on WHO Guiding Principles.  
 
 
SESSION I - Update on progress in solid organ xenotransplantation (2012-18) 
 
Dr Wayne J. Hawthorne opened this session with an introduction of participants and outline 
of the program objectives. He outlined that there had been more than 40 invited participants 
with a total of 36 invited participants attending the meeting. From these there were a total of 
25 speakers providing introduction and overview with updates of the latest innovations 
occurring in the xenotransplantation and regulatory fields. There were a total of 10 Chairs 
appointed for the various sessions of the meeting and also 6 group Rapporteurs/Chairs were 
elected for the comprehensive review of the Changsha Communiqué Principles and 
Guidance documents. The focus was to critically review;  
 New technologies,  
 Donor animal genetics,  
 Donor source herd holding requirements,  
 Changing legislative frameworks (internationally),  
 Definitions and processes for submitting clinical trial applications.  
 Emergence of a number of potential Xenotransplantation trials in islet cell, cornea and 
kidney transplantation.  




The role of the working parties was to propose changes, if required, to the guidelines and 
policy in order to safeguard mandatory safety and efficacy of imminent clinical trials.  
 
Dr Hawthorne referenced the first and second WHO Global Consultation meetings, held in 
2008 (Changsha [5]) and 2011 (Geneva [6]), respectively, and then presented the aims of 
the 3rd meeting: 
 To review the current status of xenotransplantation science and practice;  
 To determine whether updates to the Changsha Communiqué’s guidance to WHO, 
member state health regulatory authorities, and study investigators and/or sponsors 
of xenotransplantation trials are required; and  
 To discuss and refine draft consensus guidelines for infectious disease surveillance, 
prevention, and response appropriate to support various imminent clinical 
xenotransplantation trials.  
 
After presenting the program of the present meeting, Dr Hawthorne concluded his 
introduction with the remark that this WHO Global Consultation has the prospect to strongly 
reconfirm the contribution by IXA and WHO to the regulation of xenotransplantation, and to 
provide a revision to WHO Mémoire on minimizing risks in xenotransplantation with a realistic 
potential for success in pilot clinical trials in selected patients. 
 
SESSION I - Update on progress in solid organ xenotransplantation (2012-18) 
 
In this introductory update and overview session five international experts provided insight 
into current advances in the development of technologies for solid organ xenotransplantation 
and the regulatory frame works that are required to work within.  
 
Dr Muhammad Mohiuddin reviewed preclinical studies in heart xenotransplantation. 
He outlined progress in the model of heterotopic pig heart transplantation in nonhuman 
primates, with the longest survival being over 900 days: this achievement required transgenic 
expression of the complement regulator CD46 (membrane cofactor protein) and 
thrombomodulin on the background of α1,3-galactosyltransferase gene knock-out, in 
combination with costimulatory blockade using anti-CD40 antibody in the 
immunosuppressive cocktail. In long-term survivors a major contribution to rejection was anti-
non Gal antibodies. He then reviewed the achievements in the orthotopic heart transplant 
model, with special focus on the recent Nature publication by the Munich group, reporting 
survival of 195 days (protocol study endpoint with functional graft). Among the lessons 
learned in this study was the need for optimal donor heart preservation before transplantation 
and use of anti-hypertensive drugs after transplantation, and control of graft growth by 
rapamycin. Dr Mohiuddin concluded with a perspective on clinically applicable drug regimens 
and an outlook on potential clinical conditions for which cardiac xenotransplantation may be 
justified. The key points that he felt necessary to move the field forward to clinical trials were;  
 Clinically approved immunosuppression for clinical translation; 
 Experimental evidence for the benefit of additional genes; 
 Ability of multiple centers to reliably reproduce the Munich results; 
 Continuation of the dialogue with regulatory agencies and commencement of a public 
awareness campaign. 
 
Dr Joseph Tector gave an overview on preclinical studies in kidney and liver 
xenotransplantation. His presentation was based on the question of what information can be 
gained from a preclinical transplant model in nonhuman primates. Regarding kidney, survival 
data are gradually improving, with the longest survival in baboons being 260 days, and in 
monkeys 435 days. Interestingly, low levels of anti-pig antibody before transplantation were 
associated with long survival after transplantation. Also, observations in the kidneys that 
failed include features of glomerular and thrombotic microangiopathy, basement membrane 
7 
 
thickening and depositions of immunoglobulins and complement. This fits with early 
antibody-mediated rejection as a major cause of graft failure in the long term. Studies on 
donor-recipient crossmatches revealed that there is no negative crossmatch in the pig-to-
nonhuman primate model, and that the best possible combination is a donor with a knock-out 
of the β1,4‐N‐acetyl‐galactosaminyltransferase2 gene and a rhesus macaque recipient: but, 
essentially the pig-to-nonhuman primate model does not allow the assessment of a negative 
crossmatch on graft outcome. Hence, the outlook is to generate new pigs with a negative 
crossmatch. Regarding liver transplantation, Dr Tector presented data on meaningful life-
supporting function of a porcine liver in a nonhuman primate, but survival is low and more 
preclinical studies are needed using new genetic engineering strategies before considering a 
phase transition to clinical trials. 
 
Dr Agnes Azimzadeh provided a summary on preclinical studies in lung 
xenotransplantation. After an introduction on rejection mechanisms, results in an ex vivo lung 
perfusion model were reviewed. This model enables the assessment of the role of 
coagulation and inflammation, with a beneficial effect of inhibitors in the clotting reaction, 
inflammatory reactions and platelet aggregation. Regarding the coagulation cascade this was 
illustrated for the efficacy of tissue factor pathway inhibitor, thrombomodulin and endothelial 
protein C receptor. The model was used in evaluation of a large series of lungs from 
genetically modified pigs. In the model of in vivo lung transplantation into nonhuman 
primates, an increase in survival during the last years was noted, but survival rates remain 
low (up to 30 days). Dr Azimzadeh mentioned that injury of the vascular barrier function 
(leading to interstitial and airway edema) was among the significant remaining challenges.  
 
Dr Megan Sykes reviewed the current technologies and studies in the development of 
tolerance and use of regulatory T-cells. The major tolerance approaches remain focused on 
mixed chimerism and thymic transplantation. In rat-to-mouse models mixed chimerism 
prepared in combination with non-myeloablative conditioning can affect both T-cell mediated 
and non-Gal antibody-mediated rejection, and in addition induces tolerance of NK cells. 
These achievements in the rat-to-mouse model apply also to the pig-to-human combination, 
with evidence that central T-cell tolerance can be achieved through mixed pig/human 
hematopoietic chimerism. The possibility to tolerize B cells producing anti-pig antibodies may 
represent an alternative to generating knock-out pigs being deficient in carbohydrate 
epitopes. However, mixed chimerism is short-lived in the pig-to-baboon condition, with a 
major role for macrophages. To this end, transgenesis of CD47 (integrin associated protein) 
was introduced in pigs, resulting in increased porcine hematopoietic chimerism in baboons 
and prolonged porcine skin graft survival. This chimerism and skin graft survival was further 
prolonged when regulatory T-cells were added to the protocol. The beneficial effect on 
tolerance using CD47-transgenic pig donors was also evident in other transplantation 
models. The efficacy of porcine thymus transplantation was first demonstrated in pig skin 
transplantation in mice, and further developed for vascularized thymic transplants in pig-to-
baboon kidney transplantation using α1,3-galactosyltransferase gene knock-out pigs. In this 
model there was evidence for T-cell tolerance in in vitro assays. Interestingly, Dr Sykes 
mentioned that expanding the work in this transplant model revealed that CD47 transgene 
expression on glomerular cells appeared to minimize the development of proteinuria and 
nephrotic syndrome.  
 
Dr Henk-Jan Schuurman gave an overview on regulatory aspects of xenotransplantation. 
The focus of regulatory agencies is on the full flow chart, i.e., starting with the source pig 
herd and donor animal, continuing with the subsequent processing or manufacturing of the 
product, and ending with the monitoring of the patient. Reference was made to 
recommendations in earlier WHO consultation meetings. The microbiological status of the 
source herd and donor animals, in particular, with regard  to the different lists in the literature 
on excluded pathogens, and the requirements for barrier facilities. Dr Schuurman noted that 
these requirements may be less for cell therapy products than for solid organs because of 
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the time period in cell product manufacturing, with supporting data for a pig islet product. 
There is a broad regulation of cell therapy products, in contrast to that of organs: this is 
explained by the fact that a human organ in clinical transplantation is not a medicinal product. 
A proposal for release testing of a porcine xeno-organ is in preparation. Archiving and 
documentation is required for clinical application of xenotransplantation products, and it is 
proposed to implement this in collaboration between public health institutes and trial 
sponsors. Regulations of xenotransplantation are increasingly implemented worldwide, with 
major developments in Asian countries. Since the field of xenotransplantation is moving fast, 
Dr Schuurman advocated that there should be a continued dialogue between regulatory 
agencies and the science/technology arena, to reach agreement in complex issues. 
 
SESSION II a -  
Update on progress in cell and tissue xenotransplantation (2012-18) 
 
Five international experts were invited to provide an overview of the most recent 
developments in pre-clinical studies involving porcine cells/tissues. 
 
The consensus of the IXA is for rigorous pre-clinical studies focusing on the nonhuman 
primate model as a requirement prior to consideration of clinical applications. Successes in 
pre-clinical studies have led us to seriously contemplate clinical trials, emphasizing the 
importance of regulatory and ethical frameworks. In this session; 
 
Dr Rita Bottino spoke on the topic of free islet xenotransplantation. Recently, islets from wild 
type and genetically engineered pig donors have both resulted in successful treatment of 
nonhuman primate diabetic recipients. Free islets are targets of innate and adaptive 
immunity, thus far requiring high doses of islets and non-clinically applicable 
immunosuppressive drugs. Still, multiple groups worldwide have reported islet graft function 
and insulin independence, most notably the Seoul National University, which has reported 
insulin independence for more than 900 days. The further advancement of genetically 
modified pig donors, possibly using more efficient methods of genetic manipulation such as 
CRISPR/Cas 9 and the development of effective immunosuppression may lead to more 
patient friendly anti-rejection protocols that protect the xenograft without increasing the risk of 
over-treatment.  
 
Dr Jonathan Lakey outlined advances in encapsulated islet/device transplantation as a 
treatment for diabetes. Encapsulation represents the promise of islet transplantation without 
immunosuppression.  The general concept is based on a biocompatible matrix surrounding 
the islet cells that allows diffusion of oxygen and nutrients while preventing large immune 
molecules from reaching the cells, thus avoiding the host immune response. Synthetic 
agents and naturally occurring hydrogels have been used in the encapsulation process with 
varying degrees of success. Alginate encapsulation is highly popular due to its 
biocompatibility, stability, ease of use, and low cost. However, variations in alginate 
production and purification have led to issues with endotoxin content. Moreover, lack of 
knowledge regarding optimal transplantation sites and optimal donor pig strains and age has 
also contributed to inconsistent results in pre-clinical as well as in a few pilot clinical trials. 
Efforts to improve permeability and strength of the capsule have often resulted in a greater 
host biologic response to the islet transplant. Recent significant technical improvements and 
the contribution of bioengineering science have shown that it is possible to produce more 
efficient encapsulation devices. 
 
Dr Chung-Gyu Park presented an overview of the preclinical data on porcine corneal 
xenotransplantation in non-human primates carried out at the Seoul National University in 
South Korea. Both the techniques as well as the effects of different immunosuppressive 
protocols were presented. Moreover, Dr. Park focused on a proposed clinical trial of cornea 
xenotransplantation sponsored by his Institution and designed in response to the need for a 
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suitable supply of corneas to treat patients with corneal blindness. Unfortunately, the current 
supply of human donor corneas does not meet the demand in many areas of the world. The 
proposed trial is designed in accordance with the international consensus established by the 
IXA and WHO to ensure safety, efficacy and transparency. The original protocol developed 
for the trial was reviewed by a team of international multidisciplinary experts and modified in 
response to their comments. Two candidates will be enrolled in the corneal study and only 
after evaluation of the initial results will the project be allowed to proceed.  
As this will be one of the first trials of this kind, setting the precedent for the international 
community, particular attention will be paid to the safety of the procedure. To this aim, the 
sponsors and SNU have requested as a pre-requisite that national regulatory agencies 
oversee and implement all necessary regulations to provide best practice in regard to the 
protection of the general population from potential unexpected events arising from the 
proposed study.  
 
Dr Leo Buhler spoke on the topic of hepatocyte xenotransplantation. He provided an update 
of preclinical trials stating there has been one conducted at the University of Geneva where 
high volumes of alginate microencapsulated porcine hepatocytes were transplanted into the 
peritoneum of baboons immediately after induction of acute liver failure. The data 
demonstrated that the microencapsulated hepatocytes from miniature swine were able to 
provide temporary functional support for baboons with fulminant liver failure, in the absence 
of pharmacological immunosuppression. There are plans to establish a DPF pig facility and 
GMP-grade laboratory to repeat the preclinical study with a larger number of animals. 
Additionaly, mesenchymal stromal cells will be co-transplanted with the hepatocytes to 
potentially improve graft viability. The Swiss Federal Regulatory Agency for Drug 
Administration has been contacted to establish a road map for initiation of a clinical trial. 
 
Dr Megan Sykes presented an overview on transition to phase I/II clinical trials. 
The Basic Ethical principles of Respect for Persons, Beneficience and Justice predicated by 
the Belmont Report (1979) are the cornerstone of all trials, as the moral rules to follow when 
addressing specific challenges in xenotransplantation. Adherence to all applicable regulatory 
agency guidelines and international standards including the Changsha Communiqué remain 
fundamental requirements for the design of sound clinical trials.   
Important requirements should be observed in order to move forward with a porcine organ or 
tissue trial, including a patient population for whom there are no good alternatives (bridge vs 
destination therapy), justified use of immunosuppression, compelling nonhuman primate 
data, likelihood of benefit to the individual patient, and low risk to the community. To this 
aims, source animals should meet the highest biosecurity and production standards including 
quality control assessment of the gene modifications. 
Trials of kidney or heart xenotransplantation should be considered exclusively for patients 
with hyper sensitization against human antigens, who may not be able to receive a human 
organ. Treatment of fulminant liver failure via liver transplantation as a bridge to recovery or 
transplant may be contemplated, most especially in view of recent improvements in treating 
thrombocytopenia. 
Islet xenotransplantaion, an alternative to insulin therapy, may represent a more challenging 
arena to justify immunosuppression than with heart or kidney recipients. Treatment of severe 
conditions such as hypoglycemia unawareness should be evaluated and measured against 
the risk of general immunosuppression.  Protocols aimed at tolerizing the recipient towards 
the donor, thus reducing the need for systemic immunosuppression may significantly and 
positively impact the focus for islet xenotransplatation. Careful consideration should be given 
to combining islets with a kidney transplant in patients with diabetes and renal failure. 
The unique exigencies of xenotransplantation require consideration of both individual 
persons and the whole of society. Our commitment to the basic ethical principles of justice, 
beneficence, and “do no harm” remains firm. Analysis of risk and reward shows that certain 
tightly regulated clinical trials are already justified while envisioned scientific progress will 





SESSION II b - Update on GM pigs & facilities, proposed clinical trials,  
and microbiological testing 
 
Dr Ralf Tönjes chaired this afternoon session which encompassed four sections.   
 
First, Dr Eckhard Wolf gave a state-of-the-art overview on genetically-modified pigs. His 
presentation focused on methods for pig genetic engineering including the use of RNA-
guided nucleases, i.e., gene editing using CRISPR/Cas9 (Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR)/CRISPR associated protein 9), and somatic cell 
nuclear transfer. This includes the use of polycistronic vectors in transgene ‘combineering’, 
and the value of nanopore sequencing in the characterization of the transgene locus.  This 
was followed by a review of various genetic modifications generated in pigs, including the 
inactivation of PERV, and functional results achieved in transplantation. Besides gene editing 
and immunosuppression, Eckhard focused on physiology, e.g., the relevance of organ 
growth leading to the generation of growth hormone receptor-deficient pigs. The presentation 
ended with examples of specific genetic modification for islet transplantation addressing the 
instant blood-mediated inflammatory rejection (IBMIR), islet immune protection, and 
engineering to enhance insulin secretion. Dr Wolf concluded that genetic engineering of 
donor animals presents unique opportunities in xenotransplantation and has accelerated the 
progress in the field with remarkable achievements in long-term graft survival rates. The type 
of cell/tissue/organ determines the combination of genetic modifications. The cellular 
localization and level of transgene expression is crucial with respect to functionality and 
avoiding adverse side effects of a specific genomic modification. 
 
The second session was a review of the pig barrier facilities around the globe;   
 
Dr Curie Ahn gave an overview of four pig barrier facilities in Korea.  
 The Biomedical Center for Animal Resources with a capacity for 50 miniature pigs, 
originally Minnesota miniature pigs imported from the Chicago Medical School in the 
USA, and now described as SNU (Seoul National University) miniature pigs.  The 
animals are housed under designated pathogen-free (DPF) conditions. This facility 
has operated since 2002, and was described in detail regarding its infrastructure, 
including rooms for Caesarian delivery and isolator units, pig housing and herd 
monitoring. As an example, Dr Ahn mentioned the first DPF pigs expressing the 
complement regulator CD55 (human decay-accelerating factor) generated by somatic 
cell nuclear transfer.  
 The Designed Animal Resources Center with a capacity for 150 miniature pigs, with 
focus on genetically-engineered animals. The facility, in operation since 2014, 
encompasses different zones for holding miniature pigs, and has in addition a zone 
for mouse holding and a zone for holding nonhuman primates. The facility is 
equipped with all tools in advanced animal handling including the production of 
genetically-engineered pigs (CRISPR/Cas9 gene editing and somatic cell nuclear 
transfer). Dr Ahn illustrated this with various genetically-engineered pigs for use as 
donor in cell (islet) and organ xenotransplantation. 
 The Optipharm facility, which accommodates 350 miniature pigs under SPF 
conditions in two zones. The facility is in operation since 2014. The microbiologic 
monitoring was presented, based on which animals can be used as 
xenotransplantation donor. This was illustrated by the eradication of porcine 
circovirus 2 from the facility. The facility encompasses a diagnostic laboratory, the 
Optipharm Evaluation Center, for testing of infectious agents and diagnosis of animal 
diseases. 
 The National Institute of Animal Science with a capacity to house 20 pigs under SPF 
conditions and 80 pigs under DPF conditions. The facility, in operation since 2015, 
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was described regarding its infrastructure and equipment for generating genetically-
modified animals. Dr Ahn illustrated this for the first α1,3-galactosyltransferase gene 
knock-out miniature SNU pig generated in Korea, and the subsequent generation of 
animals transgenic for CD46 and thrombomodulin or CD73 (ecto-5′-nucleotidase). 
Amongst others, these animals serve as donor for cornea transplantation. 
 
Dr Wei Wang reviewed the pig barrier facilities in China. One of the major projects 
undertaken by the Central South University, Changsha group was the search for an ideal pig 
donor, the basis of an extensive search was for an animal that was negative for porcine 
endogenous retrovirus (PERV) type C, which is considered the driver for pig-to-human PERV 
transmission. After its identification, a pig line negative for PERV-C was established, and 
inbred for 22 generations. A barrier facility for DPF pigs was constructed in Changsha and 
started operations in 2012. This facility has the infrastructure and equipment to breed and 
maintain animals in DPF conditions in compliance with the regulations in China. Dr Wang 
illustrated this with the list of pathogens excluded from the herd with stringent ongoing 
maintenance and conditions such as specialized feeding. The animals in this facility were 
used as donors in a pig islet clinical trial overseen by the respective China governmental 
agency: the design of this trial was outlined in detail regarding the biosafety monitoring. This 
trial included the implementation of a database for clinical trials, and archiving of medical 
records. The trial was also registered at ClinicalTrials.gov (NCT03162237). There were no 
cross-species infections documented in this trial and importantly no cross-species 
transmission of PERV. 
Dr Eckhard Wolf gave an overview on pig barrier facilities in Europe, including a facility in 
Italy managed by Cecare Galli (Avantea) and one in Munich which accommodates pigs 
under SPF conditions. Pigs in this facility are negative for porcine cytomegalovirus, achieved 
by the immediate separation of newborns from their sows at birth, and immediate removal of 
CMV-positive sows from the herd. These pigs are used in subsequent genetic engineering 
projects, under detailed hygienic monitoring (Vaxxinova veterinary prevention strategies). 
 
Dr Agnes Azimzadeh provided a summary of pig barrier facilities in the USA. The regulatory 
landscape in the USA was introduced, with focus on guidance’s from the Public Health 
Service and the FDA. Elements for donor pigs include a closed herd in adequate barrier 
facilities, including a health screening program and monitoring for infectious agents. 
Regarding infectious monitoring reference was made to the pathogen list published at the 
WHO Global Consultation Meeting in Geneva, 2012, and a reduced list proposed by Dr Jay 
Fishman: this list was subsequently adapted based on experience with immunosuppressed 
human allotransplant recipients and experience in pig-to-nonhuman primate 
xenotransplantation studies. Two animal facilities were described; the barrier facility run by 
Spring Point Project, and the barrier facility run by the University of Alabama. The Spring 
Point facility recently published details of its operation including the monitoring regimen for 
infectious agents. The Alabama facility is presently used for generation of genetically-
engineered pigs for research projects. In a futuristic approach, the basic design of a large-
scale animal facility proposed by United Therapeutics (a US biotechnology company based 
in Maryland) was presented. This facility has a modular design to facilitate a barrier function 
and to provide expansion based on demand. 
 
The third section of this session was a review of proposed clinical trials. 
 
Dr Chung-Gyu Park described the forth coming proposed Korean clinical cornea and islet 
trials, using fresh porcine corneas and naked adult porcine islets. These trials have been 
designed following extensive consultation and focus on the global consensus (IXA and 
WHO) published in Xenotransplantation. Key items in the design are (1) the source pig; (2) 
the harvest and manufacturing of the product; (3) support data on efficacy and safety from 
preclinical transplantation in nonhuman primates; (4) outline of recipient monitoring and 
management; and (5) patient selection criteria. Donor animals are the SNU miniature pig 
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described above. The protocols were recently discussed in a meeting with the Ethics 
Committee of IXA, with input from The Transplantation Society (TTS). The cornea 
xenotransplantation is foreseen in adults who have corneal opacity and bilaterally legal 
blindness (excluding keratoconus), with primary endpoint in safety follow-up for 2 years and 
efficacy follow-up for 1 year. The islet xenotransplantation is foreseen in adults with diabetes 
for >5 years, with a first trial in 2 patients at a dose of 15,000 islet equivalents (IEQ) per kg 
body weight and a primary endpoint in a follow-up period of 16 weeks, and a subsequent trial 
being a dose escalation to determine the optimal mass of islets. 
 
Dr Joseph Tector then outlined a provisional clinical trial of porcine kidney 
xenotransplantation. The basic paradigm for the trial is based on that in human 
allotransplantation, i.e., a donor-recipient crossmatch; for xenotransplantation the elimination 
of xenoantigens is added. The question underlying a trial is whether a patient with end-stage 
renal disease can be subjected to pig kidney xenotransplantation with clinically approved 
immunosuppression and a one-year dialysis-free follow-up. Xenoantigens to be deleted are 
galactose-α-1,3-galactose (Gal), N-Glycolylneuraminic acid (Neu5Gc), and β-1,4-N-acetyl-
galactosaminyltransferase 2 (B4GALNT2). Dr Tector proposed a modification of the 
crossmatch assay used in clinical allotransplantation for application in xenotransplantation, 
because a careful identification of a crossmatch-negative patient is crucial. I this way, 
patients that are highly sensitized to HLA Class I could be unsuitable as recipient of a human 
kidney, but on the other hand have a suitable crossmatch and be eligible to receive a porcine 
kidney.  The selection of a potential recipient needs also careful attention including 
management of immunosuppression, and eligibility for a human transplant. A tiered approach 
is foreseen, with first explorations in small numbers of patients: it is realized that preclinical 
modeling lacks translational value regarding items like crossmatch. Dr Tector proposed that 
trial endpoints focus on a comparison with dialysis and not on a comparison with a human 
allograft, and also freedom of antibody-mediated rejection: these comments fit with the 
interpretation of preclinical modeling (see Dr Tector’s presentation above). 
 
The final section of this lengthy afternoon session was a review of prevention of infectious 
risk associated with xenotransplantation and current progress presented by Prof Linda 
Scobie. Initial reference was made to Principles 2 and 3 of the Changsha Communiqué, 
regulatory guidances/guidelines, and a recent thematic issue on safety in the journal 
Xenotransplantation. The presentation focused on the areas of pathogen surveillance and 
diagnostics (in both donor and recipient) and the relevance to using organs and/or cells in 
clinical trials. 
First, exogenous pathogen testing in the donor animal was described, with focus on lack of 
validated commercial diagnostic assays. The porcine islet macrobead biosafety program 
proposed by Rogosin, USA, was given as an example of good practice for surveillance of 
donor and product. This was based on a cellular xenotransplant. Along with this data, 
evidence was provided in the evaluation of islets from pig donors in a commercial high health 
swine herd from Belgium. This study demonstrated that exogenous pathogens present in the 
animal could not be found in the islet cells.  In addition, the evaluation of PERV, showed a 
reduced expression in (neonatal) porcine islets and the absence of a clear correlation 
regarding PERV expression between blood cells and pancreatic islets. Relevant was the 
observation that an alginate encapsulation product can prevent PERV transmission out of 
encapsulated islets. 
This would suggest  the possibility that infectious agents in the donor animal might not be 
considered a risk factor if these agents are not present in the final xenotransplantation 
product. Indeed, islets as a product may have significantly reduced risks compared to 
organs; this now appears to be proven questioning the need for the extensive screening 
proposed previously. 
Concerning the risk posed by PERV, Prof Scobie reviewed arguments that this risk is 
considered minimal, i.e., transmission to human cells has only been shown in vitro under 
specific conditions, and transmission in vivo has not been found including data from clinical 
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trials. Also, Prof Scobie emphasized the possibility to base an estimated risk in 
xenotransplantation on the results in allotransplantation as proposed earlier by Dr Jay 
Fishman. Overall, the need for validated commercial diagnostics, consensus protocols and 
reporting trials is still there. The presentation concluded with reference to a clinical trial with 
viable skin from miniature swine that was recently approved by the FDA and is proposed to 
begin 2019 (sponsor Xenotherapeutics, identifier NCT03695939 in ClinicalTrials.gov) 
 
Dr Henk-Schuurman chaired a short discussion sessions I and II. This discussion focused 
on the benefit to balance the risk when a xenotransplantation product is clinically applied. A 
number of key opinion leaders in the audience were asked for their views, as a prelude to the 
discussion in subsequent sessions III-V. In general, the consensus was that the progress in 
preclinical efficacy of porcine kidney and heart transplantation in nonhuman primates, 
combined with better insights into the risk, in particular the microbial risk, has resulted in an 
increased window between anticipated efficacy and safety in the clinical setting. As an 
example, the advances in orthotopic heart transplantation in baboons presented by the 
Munich group were mentioned. 
 
SESSION III a - The regulatory environment for xenotransplantation clinical 
trials 
 
This morning session, chaired by Dr Megan Sykes, provided in-depth overview of the 
regulatory environment, in particular the role of individual agencies in relation to the planning 
and conduct of xenotransplantation and clinical trials.  
 
Dr Judith Arcidiacono (FDA) presented the FDA guidelines/policy to undertake clinical trials 
of xenotransplantation.  After an introduction in which xenotransplantation products were 
defined and the revised FDA Guidance was mentioned, the FDA Centers involved in 
oversight were introduced. The risks of xenotransplantation products were presented in 
detail, and also the four target items in regulatory considerations, i.e., the source herd, the 
source animal, the processing and manufacture of the product and the monitoring of patients. 
This was further specified for the three types of products, i.e., whole organs, cells and 
tissues, and combination products (cells and device). The action items and interactions with 
FDA during the different phases of product development, i.e., preclinical, clinical, and 
marketing, were presented. Special attention was given to possible risks associated with 
genetically-altered source animals, with requirements for an Investigational New Animal Drug 
(INAD) and New Animal Drug Application (NADA). Dr Arcidiacono concluded this 
comprehensive overview with a summary of new references in the 2016 Guidance, a list of 
FDA Guidance documents, and contact information. 
 
Dr Jianguo Xu described the infectious disease surveillance and control system in China. 
This included the notifiable disease reporting system for 39 diseases in three different 
categories. This system is internet based centered around a data center (Chinese Center of 
Disease Control). An enhanced surveillance has been introduced for 27 selected diseases 
and 4 vectors (rat, mosquito, fly, cockroach). Also, a public health emergency reporting 
system has been established. Dr Xu finished the presentation with an outline of the strategy 
for different groups of diseases, and data on morbity and mortality trends of infectious 
diseases during the last decades. 
 
Dr Minhua Luo described the system for monitoring and control of viral infections in 
xenotransplantation recipients in China. This centered at the Wuhan Institute of Virology of 
the Chinese Academy of Sciences, and the National Biosafety Laboratory. The activities 
were introduced by two cases of lymphocytic choriomeningitis virus infection in renal 
allotransplant recipients. The need for biosafety surveillance was recognized during the 2008 
Changsha meeting [5] and the pig-to-human xenotransplantation summit in Changsha held in 
2012 (published in Xenotransplantation 2012; 19: 327-328). Dr Luo presented an overview of 
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PERV, in relation to Human Endogenous Retrovirus (HERV), and introduced a sensitive 
high-throughput screening for virus infection surveillance. Thereafter an overview of human 
cytomegalovirus in transplantation and immunocompromised individuals was presented, 
ending with the introduction of a novel antiviral drug, Letermovir, which is now in a late stage 
of development. 
 
Dr Ralf Tönjes introduced the EU guidelines and policy to undertake clinical trials. Clinical 
trials in Europe are centered around Regulation (EU) No 536/2014. This regulation 
comprises 16 chapters. Out of these, the chapter on the authorization procedure for a clinical 
trial was presented in detail: this included the timelines and activities between document 
submission, document assessments and assessment reports, responses regarding the 
document and the decision on approval of the trial. Reference was made to a publication 
presenting the flow chart of this regulation in Nat Biotech 2016; 34: 231-233. Dr Tönjes then 
described the Medicinal Products Act in Germany, and the procedure in application for a 
clinical trial developed by the Paul Ehrlich Institute: the folder structure of the documentation 
was explained. A special folder is included that deals with xenogenic products. Dr Tönjes 
finished his presentation with the introduction of the EU Guideline on Xenogeneic Cell-based 
Medicinal Products issued by the European Medicines Agency in 2009, and the EU 
regulation 1394/2007 on Advanced Therapy Medicinal Products, which are key documents in 
clinical development of xenogeneic cell-based therapy. 
 
SESSION III b - The role of IXA and WHO in the regulation of 
xenotransplantation 
 
Dr Emanuele Cozzi chaired this session, which provided insight to the continued strengths 
in the relationships between the IXA and the WHO in ensuring the appropriate guidance is 
provided in relation to potential xenotransplantation clinical trials. 
 
Dr Robin Pierson presented a summary of the IXA-FDA meetings in Boston (2016) and 
Baltimore (2017), and the role of the IXA Ethics Committee, which he chairs. The meeting in 
Boston was held during the American Transplant Congress and was attended by IXA Council 
members and representatives from the FDA. A number of regulatory topics proposed for re-
consideration which were discussed, among which the relevance of PERV as a pathogen for 
humans, the requirement of 50 years in archiving materials from xenotransplantation 
recipients, and the classification of genetically-engineered pigs. Also, some points that are 
specifically related to islets were part of the discussion. As a follow-up to this meeting, a joint 
FDA-IXA symposium was held preceding the IXA congress in Baltimore in 2017 (published in 
Xenotransplantation 2017; 24: e12365): during this symposium xenotransplantation experts 
presented overviews on recent scientific advances in xenotransplantation, infectious safety 
aspects and risk-benefit analysis, and FDA representatives addressed various aspects of 
regulatory considerations. Among the outcomes of this symposium were (1) the conclusion 
that progress in the field has rendered the risk/benefit ratio more favorable for both the 
individual study subject and for society, and (2) the confirmation of the shared goal of FDA 
and IXA in advancing and protecting public health through the development of safe, effective 
xenotransplantation products. Dr Pierson finished his presentation by reminding attendees of 
the mission of IXA and emphasizing the role of the IXA Ethics Committee: a number of 
activities of the Ethics Committee since its introduction in 2003 [3] were presented. 
 
SESSION IV - Review of Changsha Communiqué Principles and Guidance 
 
Dr Emanuele Cozzi presented his views on how we have moved on since the 
Recommendations of the 2nd WHO Global Consultation (Geneva 2011). He started with a 
summary of the recommendations and addressed a number of items for revision. Dr Cozzi 
highlighted a number of points presented earlier in the meeting, in introducing the following 
points for discussion (which were further discussed in working groups described below): 
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1. Xenozoonosis: there are multiple lists of infectious agents to be excluded from the 
donor pig and xenotransplantation product: also, the donor animal and 
xenotransplantation product can differ in presence of infectious agents. Finally, there 
are new developments in PERV monitoring.   
2. Regulatory aspects: new or updated documents have been issued in Europe and 
USA, and there are relevant developments in establishing regulatory networks in 
Asian countries. 
3. Biorepository: there is ongoing discussion about materials to be archived, storage 
location, responsibility and financial support, and time of storage. 
4. Pig facilities: barrier conditions have been defined, but there is a central question 
about the definition of ‘clean’ pigs. 
5. Biomaterials and encapsulation: there are a number of developments and innovations 
in islet encapsulation strategies, aiming to keep islets alive, prevent a destructive host 
response and assure practical surgical implantation.  
6. Immunosuppression and tolerance induction: there is the ongoing discussion (1) 
whether efficacy and safety should always be validated in a nonhuman primate 
model; (2) whether non-life-saving xenotransplantation products like kidney or cornea 
should be applied as new, innovative and possibly life-threatening regimens; (3) 
whether any new drug (even not approved) can be considered in combination with a 
xenotransplantation product; and (4) on the translational  value of efficacious 
strategies in an animal model.   
 
Dr Wayne Hawthorne established working groups to revisit the guidelines post-Geneva. Dr 
Hawthorne outlined the process to achieve the second and third aims of the meeting, i.e., to 
assess whether updates to recommendations from previous WHO meetings were required; 
and to discuss and refine draft consensus amendments for infectious disease surveillance, 
prevention, and response, appropriate to support various imminent clinical 
xenotransplantation trials.  
 
To this end, participants were divided into six working parties in relation to their particular 
areas of expertise, and a Chairperson and Rapporteur were voted as representatives for 




4. Transgenic pig Facilities 
5. Biomaterials and Encapsulation 
6. Immunosuppression and Tolerance Induction 
 
The task given to the defined groups was to review the guidelines and policies, in particular 
the Recommendations to Undertake Clinical Trials, in relation to the previous WHO Global 
Consultation Meetings  (the Changsha Communiqué of 2008 [5], and the Geneva meeting of 
2011 [6]), and to propose any necessary amendments. 
 
After discussion in each working party, the proposed amendments were presented and 
discussed in a plenary session. This was followed by further refinement of the individual 
points raised. At the end of the meeting these amendments were to be finalized and phrased 
as a proposed change in the respective recommendations to WHO, Member State health 
regulatory authorities, and study investigators and/or sponsors of xenotransplantation trials.  
 
SESSION V - Summaries from Working Parties 
Main summaries regarding the Principles in the Changsha Communiqué 
 
The working parties agreed unanimously on several modifications and amendments to the 
original recommendations in order to reflect the developments that have occurred since the 
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previous WHO Global Consultation Meetings. 
 
The Changsha Communiqué begins with a list of 10 Principles that guide and inform the 
WHO position on regulatory requirements for xenotransplantation clinical trials. As we rapidly 
approach the possibility of clinical trials conducted under WHO guidance, it becomes a 
practical matter to define the scope of xenotransplantation as it relates to these guidelines. 
 
Principle 1 has, therefore, been amended to define xenotransplantation based on the 
definition of the US FDA. Thus, xenotransplantation is considered as any procedure that 
involves the transplantation, implantation or infusion into a human recipient of either (a) live 
cells, tissues, or organs from a nonhuman animal source, or (b) human body fluids, cells, 
tissues or organs that have had ex vivo contact with live nonhuman animal cells, tissues or 
organs. This specifically excludes the transplantation or implementation of acellular animal 
tissues, (described as “xenograft” in the revised 2016 FDA Guidance, which are beyond the 
intended scope of the document).  
 
In order to better reflect the advanced state of preclinical xenotransplantation, Principle 1 has 
been amended to read that xenotransplantation, rather than “successful” 
xenotransplantation, has the potential to treat a wide range of serious diseases.  
 
Principle 4 discusses the importance for clinical trials to be effectively regulated by the 
relevant governmental authorities and has been amended to emphasize the importance of 
monitoring post-market entry after regulatory approval of a safe, effective 
xenotransplantation product.  
 
Principle 7 focuses on the long-term storage of animal and patient samples and records, 
even to the extent of providing for succession in the event that the original proposers of the 
clinical trial are unable to continue. It has been revised to emphasize that succession should 
also be assured for surveillance of the patients in addition to samples and records.  
To highlight the advances in xenotransplantation and the likelihood of clinical trials, the 
language of Principle 10 has been modified to indicate that equitable access should be given 
to “effective xenotransplantation therapies.”  
 
SESSION VI - Summary and Revision to WHO Mémoire on Minimizing Risks in 
Xenotransplantation 
 
The third and final day commenced with Dr Peter Cowan revisiting and prioritizing essential 
requirements for clinical trials followed by Dr Jose Nuñez outlining the revision to the WHO 
Mémoire on minimizing risks in xenotransplantation and its relationship to the Changsha 
Communiqué. During these last sessions Dr Nuñez also helped to guide the group in its final 
revisions and summation of the Communiqué so that it was able to incorporate the essence 
of the original 2008 Communiqué and the 2011 updates.  
 
This final session was the practical summation of the previous two days’ work specifically the 
incorporation of the revisions, modifications and additions undertaken to the original 2008 
Communiqué and the 2011 update document. In total more than 100 changes reflecting the 
developments that have occurred since the previous WHO Global Consultation Meeting were 
agreed upon by all participants and written into the original 2008 Changsha Communiqué.   
 
Dr Richard Pierson provided a short overview of the way forward and next steps to be taken 
to finalize the document from the meeting, and all in attendance agreed that there should be 
regular review and updating of the Communiqué. Dr Agnes Azimzadeh (IXA President 
Elect) gave a final conclusion and summary and thanked all participants on behalf of the IXA 




The meeting was closed by the Program Chair Dr Wayne Hawthorne and the Local 
Organising Committee Chair Dr Wei Wang, who thanked all those who had helped in the 
organisation and running of the meeting to make it such an overwhelming success. They 
also praised the meeting sponsors including the IXA and the TTS, whose support in planning 
and organisation was acknowledged.  Special thanks was also given to the WHO for once 
again convening this important global meeting, and to the Third Xiangya Hospital and the 
Central South University of Hunan Province, China for their generous sponsorship, without 
which the meeting could not have taken place.  
 
The draft amended Principles and Recommendations were finalized shortly after the 
meeting, and were submitted to WHO in February 2019 for approval and publication. After 
approval, this document will be published on the website of WHO and TTS (IXA website), 
and in Xenotransplantation. Below is the summary of the modifications to the 
recommendations. 
 
Main summaries regarding the Recommendations in the Changsha 
Communiqué 
 
Key recommendations follow the Principles established in the first section of the Changsha 
Communiqué. Language was modified throughout the document from “must” to “should”, in 
order to better reflect the purpose of this document as a series of guidelines without legal 
authority. 
 
Recommendation 4 to WHO emphasizes the role of WHO in promoting public awareness of 
both the benefits of xenotransplantation, as well as the awareness of dangers associated 
with unregulated xenotransplantation. Reflecting the developments in genetic engineering of 
source animals since the Global Consultations in 2008 and 2011, WHO has charged itself to 
promote the enhanced opportunity for potential clinical trials provided by the use of animals.  
 
The majority of recommendations, however, have been directed toward the investigators and 
sponsors of clinical trials using xenotransplantation products. Several amendments or 
modifications highlight the importance of genetically-engineered source animals including 
Recommendation 1 to investigators which has been updated from “specific” to “designated” 
pathogen-free animals to reflect current understanding of the conditions necessary to utilize 
specially-bred animals for xenotransplantation.  
 
The new Recommendation 2 to investigators indicates that investigators should develop 
quality control measures and standards for genetically-modified pigs to ensure the desired 
phenotype and function of the xenotransplantation product. Recommendation 8 to 
investigators parallels the above recommendation to WHO in promoting public awareness of 
xenotransplantation, which serves to underscore the importance placed on regulation of all 
aspects of xenotransplantation in order to provide optimal safety and efficacy. 
 
Recommendation 4 to investigators discusses the importance of utilizing reproducible 
preclinical data, usually from testing in nonhuman primates, as the basis of designing a 
clinical trial. It has been updated to point out that preclinical studies should be modeled as 
closely as possible to clinical regimens in order to yield more relevant results. 
 
Recommendation 10 to investigators encourages the storage of appropriate specimens from 
patients and source animals in accordance with national regulatory guidelines and standards 
in quality management, and this includes a provision for stewardship of all records, data and 
archived samples.  
 
A new Recommendation 10 to investigators states that devices and biomaterials should 
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comply with current international standards that were not in place at the time of the original 
Changsha Communiqué.  
 
Finally, it was unanimously approved by the participants in the present meeting to explore 




This third WHO Global Consultation Meeting proved to be very successful and productive in 
many aspects. Clinical application of xenotransplantation has been pursued for decades (or 
even centuries), but implementation that is accepted in regulatory clinical practice is of more 
recent date. Initiatives in this respect by respective societies and institutions are illustrated by 
the founding of IXA in 1996, the first publication by regulatory agencies (US PHS Guideline 
published in 2001), and the WHO resolution 57.18 in 2004. The continued need for close 
interaction between innovative science and technology, regulatory affairs, and 
implementation at the global level, is illustrated by the outcome of the present 2018 
Changsha WHO Global Consultation Meeting. Representatives from all disciplines involved 
came together to discuss progress and innovations in the field, mirror this progress with 
respect to regulatory oversight, and foster this at the global level under the umbrella of WHO. 
The need for such meetings is evidenced by innovations in the field and resulting 
amendments in regulatory oversight and recommendations in the WHO Mémoire to 
synchronize developments between different countries across the globe. The perspective of 








Special thanks are to Dr Judith (Horvath) Arcidiacono from the Office of Tissues and 
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Administration, who attended the meeting on behalf of the FDA and presented the FDA 
guidelines/policy to undertake clinical trials. Besides giving this presentation in session III, 
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OVERVIEW OF THE THIRD WHO GLOBAL CONSULTATION ON REGULATORY 
REQUIREMENTS FOR XENOTRANSPLANTATION CLINICAL TRIALS 
 
Wayne John Hawthorne 
Department of Surgery, Westmead Clinical School, University of Sydney 
National Pancreas and Islet Transplant Laboratories, Westmead Hospital, Westmead 
Centre for Transplant and Renal Research, Westmead Institute for Medical Research 
INTRODUCTION: The Third WHO International Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials (“10 year review of the Changsha Communiqué”) is 
convened once again in Changsha, China, 12-14 December 2018. The meeting 
commemorates a decade since the initial “Changsha Communiqué” International Consultation 
on Xenotransplantation was held in Changsha, China, 19-21 November 2008, and seven 
years since The Second WHO International Consultation on Regulatory Requirements for 
Xenotransplantation Clinical Trials ("Geneva Consultation") convened at WHO headquarters 
in Geneva, Switzerland, on October 17-19, 2011. The Third Consultation was initiated by the 
International Xenotransplantation Association (IXA) with support from The Transplantation 
Society (TTS) together with the WHO. Invited delegates including international health 
regulatory authority representatives and internationally recognized experts in 
xenotransplantation science, technology, law, and ethics from most WHO regions, 
representing a substantial number of WHO member states. The charge to delegates and 
outcomes for the Communiqué are: 
1) To review the current status of xenotransplantation science and practice; 
2) To determine whether updates to the Changsha Communiqué’s guidance to WHO, 
member state health regulatory authorities, and study investigators and/or sponsors of 
xenotransplant trials are required; and 
3) To discuss and refine draft consensus guidelines for infectious disease surveillance, 
prevention, and response, appropriate to support various imminent clinical 
xenotransplantation trials. 
The program is based on the principals and guidance documents of the previous 
Communiqué: working groups are created to revisit the guidelines post-Geneva. The 
program will critically review the Changsha Communiqué Principles and Guidance, revisiting 
and prioritizing essential requirements for clinical trials. In particular working parties will 
address the necessity to revise guidelines and policy in undertaking clinical trials. Through 
presentations they will formulate the changes required to the guidelines and policy in order to 
safeguard safety and efficacy of imminent clinical trials. 
DISCUSSION: The reasoning behind the present WHO consultation is the substantial 
progress in the field of Xenotransplantation during the past several years, specifically in 
regards to the development of new technologies, donor animal genetics, donor source herd 
holding requirements, changing legislative frameworks (internationally), definitions and 
processes for submitting clinical trial applications. This is along with the emergence of a 
number of potential applications for Xenotransplantation trials in islet cell, cornea and kidney 
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transplantation. The development of the regulatory requirements for such clinical trials will be 
revised along with the requirements for comprehensive safety, efficacy, longevity and 
monitoring of the transplanted cells, tissues, or organs. 
CONCLUSION AND/OR RECOMMENDATIONS: This WHO Global Consultation has the 
prospect to strongly reconfirm the contribution by IXA and WHO in the regulation of 
xenotransplantation, and to provide a revision to WHO Mémoire on minimizing risks in 









PRECLINICAL STUDIES: ADVANCEMENTS IN CARDIAC XENOTRANSPLANTATION 
Muhammad M Mohiuddin 
University of Maryland School of Medicine, Baltimore, MD 
INTRODUCTION AND DISCUSSION: Recently there has been a surge in reports describing 
fantastic survival results for solid organ xenotransplantation. Our group and others continue 
to show significant improvement in survival of cardiac xenografts in a heterotopic pig-to-
baboon heart transplantation model. This presentation will highlight some significant 
advances in the field of heart xenotransplantation in large animal models. A major reason for 
the improved graft survival is the advancement in the technology, including CRISPR-Cas9 
technique, to genetically modify the donor pigs and make their organs and tissues less 
immunogenic to nonhuman primates and humans. Some of the major genetic modifications 
will be discussed along with their specific impact on averting xenograft rejection of 
heterotopic cardiac xenograft. Another development that has significantly helped 
xenotransplantation research is the availability of target specific antibodies, to block specific 
immune pathways, like CD40-CD40 ligand mediated costimulation pathway, which have 
made a significant impact in the advancement of this field by suppressing rejection. The 
specific role of these antibodies in preventing xenograft rejection will also be discussed. Dr 
Bruno Reichart’ s group from Munich, Germany, has reported significant pig cardiac 
xenograft graft survival in orthotopic position and some of the information presented by this 
group at the transplantation meetings will be briefly discussed. Other major factors that have 
also been very helpful are: the utilization of novel monitoring methods for the graft function 
and improvements in methods to manage post-operative transplant animals, especially the 
ability to detect complications at an early stage with the ability to overcome these adverse 
effects. 
CONCLUSION: Finally, the impact of the above advancements in bringing 
xenotransplantation to the clinic and potential remaining hurdles for clinical translation will be 
reviewed. 
 
PRECLINICAL STUDIES: KIDNEY AND LIVER XENOTRANSPLANTATION 
Andrew Adams1, Matthew Tector2, Joseph Tector2 
1Emory University School of Medicine, USA, 2University of Alabama, Birmingham, USA 
INTRODUCTION: Kidney xenotransplantation: The shortage of suitable donor organs has 
pushed the need for xenotransplantation to the forefront of transplant research. Genome 
editing tools for use in pigs has improved dramatically in the last 5-10 years, paving the way 
for the creation of new donor pigs with fewer xenoantigens, and human transgenes that can 
downregulate the recipient immune response. While there are a significant number of 
waitlisted patients with no detectable xenoreactive antibodies to new xenoantigen-deleted 
pigs, there is no case where a primate has a negative crossmatch. Nonhuman primate 
recipients with high pre-transplant donor antibody levels reject renal xenografts in less than 6 
days, but multiple groups have shown prolonged kidney xenograft survival past 180 days is 
feasible in recipients with more favorable pre-transplant crossmatches using costimulatory 
blockade-based immunosuppression.  Human transgenes (complement regulation and 
thromboregulation) are helpful in preventing early antibody-mediated rejection, but renal 
xenograft failure is still secondary to antibody-mediated rejection in all cases. Results using 
calcineurin-based immunosuppression regimens are less favorable, with graft survival rarely 
going past 20 days, regardless of the crossmatch status. While these results are 
discouraging, they are not different than the survival achieved in crossmatch-positive renal 
allotransplantation in non-human primates. 
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Liver xenotransplantation: The need for more liver donors is significant, but clinical 
application of liver xenotransplantation has been prevented because of the thrombocytopenia 
that occurs immediately following graft reperfusion. The best survival in a pig-to-nonhuman 
primate model of liver xenotransplantation approaches one month. The thrombocytopenia 
was overcome by infusing human coagulation factors.  The cause of failure in the recipients 
going out past two weeks was aberrant clotting and thrombosis of major vasculature. There 
is a need for new genetic engineering strategies to overcome the thrombocytopenia, and 
eliminate the need for infusion of exogenous coagulation factors. The deletion of 
Asialoglycoprotein Receptor 1 in pigs decreases the platelet removal from ex-vivo perfusion 
circuits, but this strategy has not been tested in vivo in a preclinical model. 
DISCUSSION AND RECOMMENDATIONS: Kidney xenotransplantation: Improving survival 
in preclinical models will depend upon the identification and elimination of new xenoantigens 
on the surface of pig cells. If a crossmatch-negative xenograft can be performed in a 
preclinical model, it will be possible to evaluate whether calcineurin-based 
immunosuppression can prevent cell-mediated xenograft rejection well enough for clinical 
trials. 
Liver xenotransplantation: It is likely that bridging trials where a patient with significant 
liver failure is transplanted with a pig liver to stabilize them until a human liver can be found 
will be the initial clinical application for liver xenotransplantation. Significant work needs to be 
done using newly available pig livers in a preclinical model before moving forward with 
clinical application. 
 
PRECLINICAL STUDIES: LUNG 
Agnes Azimzadeh 
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, 
Boston, MA, USA 
INTRODUCTION: Substantial progress has recently been observed in understanding the 
mechanisms of injury in lung xenotransplantation, and overall in vivo lung xenograft survival 
and function. Removal of the main carbohydrate antigen recognized by human anti-pig 
antibodies (alpha-gal) prevented the immediate destruction of pig lungs by human blood. The 
knockout of additional “non-Gal” carbohydrate gene targets (Neu5Gc, beta-4Gal) added 
incremental benefits. The addition of specific human genes (transgenes) expressed on the 
alpha-galactosyl transferase-deficient background demonstrated important roles for 
complement regulation (membrane cofactor protein, CD46), coagulation pathway 
dysregulation (endothelial protein C receptor, tissue factor pathway inhibitor, von Willebrand 
factor) and NK cells (HLA-E), as shown by improvements of specific parameters in ex vivo 
lung perfusion experiments. At the last IXA meeting, survival for over one week of pig lungs 
in baboons has been reported by two groups. 
Although the lung represents a very difficult organ xenotransplant model, these 
results present very substantial progress, highlighting the potential of genetic modifications to 
prevent xenotransplant injury mechanisms. Moving forward, data from ex vivo and in vitro 
perfusion models identify platelet and neutrophil adhesion, monocyte/macrophage activation, 
glycan-based cellular adhesive interactions and specific pro-inflammatory cytokines, as 
logical targets for additional interventions. Future studies will address these residual injury 
mechanisms either through genetic modifications of the donor pig, or using pharmacologic 
treatments. In addition, immunosuppression or immunomodulation of the recipient will be 
tailored to avoid and promote immune tolerance. 
 
PRECLINICAL STUDIES: TOLERANCE AND REGULATORY T CELLS 
Megan Sykes, David Ayares, Adam Griesemer, Robert Hawley, Hao-Wei Li, David H. Sachs, 
Kazuhiko Yamada 
Columbia University, New York, USA 
INTRODUCTION: The immune and non-immune barriers to xenografts are even stronger 
than those to allografts. The ability to genetically engineer source animals has improved 
outcomes of pig-to-primate xenotransplantation, but high levels of immunosuppression are 
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required with many side effects, and graft rejection nevertheless eventually occurs. While the 
development of the αGal-knockout pig has been a major advance, studies in nonhuman 
primates indicate that other, non-Gal, natural antibody specificities can be targets of rejection 
when transplanting αGal-knockout (GalT-KO) organs.  Several carbohydrate targets of anti-
non-Gal natural antibodies have been identified and the genes producing enzymes that 
generate these epitopes have now also been knocked out. However, these additional 
knockouts appear to express new epitopes recognized by baboon natural antibodies. 
Induction of immune tolerance, in which the recipient’s immune system treats the 
donor as “self’, eliminates responses to donor antigens, including these newly revealed 
determinants, avoiding the need for long-term immunosuppression while assuring long-term 
graft survival. Tolerance is therefore particularly desirable in the challenging setting of 
xenotransplantation. 
DISCUSSION: Studies in rodents and humanized mice have demonstrated the efficacy of two 
methods of tolerance induction, namely pig thymus transplantation and induction of mixed 
hematopoietic chimerism. Induction of mixed xenogeneic chimerism can simultaneously 
achieve tolerance of natural antibody-producing B-cells recognizing known and unknown 
specificities, T cells and natural killer (NK) cells, all of which pose significant barriers to 
xenotransplantation. Moreover, mixed chimerism can be achieved with relatively non-toxic 
conditioning regimens that overcome the immune barriers to the xenogeneic species, which 
include several components of the innate immune system in addition to T cells. The use of a 
human CD47-transgenic source pig and intrabone injection of the bone marrow greatly 
enhances mixed chimerism and tolerance induction in the pig-to-baboon model, achieving 
promising pig kidney graft outcomes. 
An additional approach to enhancing pig chimerism in the baboon model involves 
infusion of expanded regulatory T-cells from the recipient along with pig hematopoietic cells. 
This approach has enhanced pig skin graft survival on baboons. Simultaneously, our group 
has pursued the approach of recipient T-cell depletion combined with pig thymus 
transplantation. Proof of the efficacy of porcine thymic transplantation in inducing human T-
cell tolerance has been obtained in humanized mouse models, in which diverse, normal 
human T-cells develop in porcine thymic xenografts and are tolerant to the porcine donor, the 
recipient mouse and the human hematopoietic stem cell donor. This approach has been 
extended to the pig-to-baboon combination using vascularized pig thymus grafts. Sustained 
life-supporting porcine kidney xenograft survival has been achieved reliably with this 
approach, with evidence for the development of T-cell tolerance to the donors. 
CONCLUSION AND/OR RECOMMENDATIONS: Using existing genetic modifications of 
porcine source animals, it seems likely that tolerance and graft survival without chronic 
immunosuppression should be achievable in the pig-to-human combination within the near 
future. This approach would be optimal in view of the very strong immunologic barriers to 
porcine xenotransplantation. Given the time required for generation and approval of a clinical-
grade source pig, efforts to obtain this status for GalT-KO, hCD47-transgenic source pigs in 
anticipation of clinical trials are currently justified. 
 
PRECLINICAL STUDIES: REGULATORY ASPECTS 
Henk-Jan Schuurman 
SchuBiomed Consultancy BV, Utrecht, The Netherlands 
INTRODUCTION: Paragraph 4 of the Changsha Communiqué (2008) states “Because of 
these wider community risks, xenotransplantation clinical trials and procedures need to be 
effectively regulated. There should be no xenotransplantation in the absence of effective 
regulation by the government of the country. Regulation should have a legal basis with 
powers to ban unregulated procedures and enforce compliance with regulatory requirements. 
“The regulatory system should be transparent, must include scientific and ethical assessment 
and should involve the public”. At that time major regulatory documents were from USA, i.e., 
the Public Health Service Guideline on Infectious Disease Issues in Xenotransplantation 
(2001), and the Xenotransplantation Guidance for Industry from the Food and Drug 
Administration (FDA, 2003, updated in 2016). Also, in New Zealand the Health Research 
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Council had issued Guidelines for Preparation of Applications Involving Clinical Trials of 
Xenotransplantation (2007); this document is noteworthy, because the first clinical trials 
under proper regulatory oversight were conducted in this country (porcine islets for the 
treatment of diabetes, approved in 2007). 
Much has happened since the 2008 WHO Global Consultation meeting in Changsha. 
A few examples are worth mentioning. The European Medicines Agency issued in 2009 the 
Guideline on Xenogeneic Cell-based Medicinal Products, and the revised guidance 
"Guideline on quality, non-clinical and clinical aspects of medicinal products containing 
genetically modified cells" is presently under public consultation. In 2017 the FDA released 
the Draft Revised Guidance #187 “Regulation of Animals with Intentionally Altered Genomic 
DNA”. In Australia, goods that comprise or contain live animal cells, tissues or organs are 
since 2017 regulated as biologicals. In Japan new or amended jurisprudence that affect 
xenotransplantation products was introduced in 2013, namely the Act on the Safety of 
Regenerative Medicine, and the Pharmaceutical and Medical Devices Law. In South-Korea 
the Ministry of Health and Welfare is developing a legal frame work for xenotransplantation, 
which is relevant in view of prospected xenogeneic cornea trials. In China the oversight of 
clinical trials has assigned to the National Health and Family Planning Commission, the 
former Ministry of Health.  
According to the general definition, xenotransplantation products encompass live 
organs, tissues, and cells. These products are regulated in different ways. Human donor-
derived organs are not considered as medicinal products, i.e., organ transplantation is 
regulated differently as drugs/biologicals; on the other hand, for cell therapy  - either 
autologous, allogeneic or xenogeneic - a large regulatory framework has been developed 
worldwide during the last two decades. Noteworthy, non-live xenogeneic material is not 
considered a xenotransplantation product in regulatory terms; this is exemplified by the 
designation “xenograft” in the recently updated FDA Guidance, and the regulation as a 
medical device by most regulatory agencies. Therefore, regulatory xenotransplantation 
documents focus on safety, in particular the potential cross-species transmission of infectious 
agents after entry in the host. To this end, the FDA Guidance has introduced a new status of 
pathogen presence, designated pathogen-free (DPF), a status in between specific pathogen-
free (SPF) and gnotobiotic. 
For the swine species, generally accepted as the donor species for 
xenotransplantation, the DPF status regards two major items. First, the presence of 
xenozoonotic exogenous infectious agents that do not affect the health status of the donor 
animals, but can infect and cause disease in a human recipient; e.g., herpes viruses such as 
gamma-lymphotropic herpesvirus, cytomegalovirus, and hepatitis E. Second, the presence of 
endogenous agents, i.e., Porcine Endogenous RetroVirus (PERV). Exogenous infectious 
agents can be eliminated from the herd by various breeding techniques in herd maintenance: 
in case of cell therapy products, exogenous agents can also be eliminated from the final 
product by various procedures during the manufacturing process starting with organ 
procurement and ending with cell culture. Regarding PERV, since the recognition of pig-to-
human transmission in a rather artificial cell coculture condition 20 years ago, the status of 
present knowledge indicates that the potential of cross-species transmission is minimal and 
manageable. Also, gene-editing technology (such as CRISPR-Cas9) has been introduced 
which is claimed to inactivate the genes encoding PERV sequences. 
CONCLUSION AND/OR RECOMMENDATIONS: Regulatory agencies have followed the 
progress in xenotransplantation research to enable the phase transition to clinical 
development under proper regulatory oversight. It is realized that xenotransplantation 
products encompass different products (organs, tissues, cells) that share microbial safety 
aspects, but differ in regulatory aspects addressing efficacy and functionality in development 
and market approval. These products also share regulatory aspects of genetically modified 
donors. Xenotransplantation products are based on innovative and new biomedicinal 
approaches, and therefore a continued dialogue between the xenotransplantation field and 
regulatory authorities is warranted to address risks and risk management in bringing 
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xenotransplantation products to clinical application in patients with end-stage organ 
dysfunction who are in medical need for treatment of their disease. 
 
 




PRECLINICAL STUDIES: FREE ISLETS 
Rita Bottino1, David KC Cooper2, Massimo Trucco1 
1Allegheny Health Network – Carnegie Mellon University – Pittsburgh, PA, USA 
2University of Alabama at Birmingham, Birmingham, AL, USA 
INTRODUCTION: Islet transplantation is a valuable alternative to whole pancreas 
transplantation to treat diabetes and reduce the life threatening hypoglycemia unawareness in 
patients with Type 1 diabetes. Paucity of human organ donors has led to the consideration of 
potential alternative sources of islets, with pig islet cells being attractive candidates for cell 
therapy. One of the compelling reasons for choosing the pig is the long experience in the use 
of porcine insulin to treat patients before recombinant human insulin became available. 
Porcine insulin demonstrates its biological function in humans. Validation of isolated pig islets 
as a viable insulin-producing tissue for transplantation has been consistently achieved in 
immunodeficient rodent recipients.  Over the last 15 years, more rigorous animal models such 
as the pig-to-nonhuman primate transplantation model have been studied. Consensus has 
been reached within the International Xenotransplantation Association on the relevance of 
pre-clinical studies in nonhuman primates prior to initiating clinical trials. More specifically, 
proof-of-concept that porcine islets transplanted in diabetic immunosuppressed nonhuman 
primate recipients consistently improve metabolic control, is regarded as a key milestone to 
be met before human applications. 
Porcine islets can be isolated from the pancreas of adult and neonatal pigs with 
consolidated yet challenging procedures. Islets from genetically-engineered pig donors (with 
tissues devoid of the alpha-Gal epitope that is target of anti-Gal natural antibodies, and 
transgenic expression of human factors modulating inflammation and coagulation) and islets 
from wild-type (non-genetically manipulated) pigs, have been successfully used in nonhuman 
primate recipients. Free islets (thus non-encapsulated, non-immunoisolated) are the target of 
innate and adaptive immunity. Immunosuppression of the recipient is therefore necessary for 
graft survival. Using relatively high islet doses and efficacious, yet not clinically applicable, 
immunosuppression, islet graft function and insulin independence have been achieved by 
many groups worldwide, with most recent data from Seoul National University reporting 
insulin-independence for more than 900 days. 
DISCUSSION: Comparison of metabolic profiles in humans, nonhuman primates and pigs 
suggests that porcine islets may perform more efficiently in humans than in nonhuman 
primates. High islet doses are required to overcome the initial islet loss due to inflammation 
and innate immunity. Improved peritransplant management may prove critical to reduce such 
loss. In addition, the need for immunosuppression that is clinically applicable, thus that carries 
minimal additional risk to the patient than conventional anti-rejection protocols, remains an 
unresolved challenge. A combined effort consisting in (i) the choice of effective genetic 
modifications for pig donors, and (ii) selection of immunosuppressive drugs that protect the 
graft without increasing the risk of over- immunosuppression, may be appropriate. 
CONCLUSION AND/OR RECOMMENDATIONS: Progress has been made in the pig-to-
nonhuman primate models of islet transplantation. In view of clinical translation, the 
availability of genetically-engineered pig tissue provides a helpful tool to improve compatibility 
between donors and recipients.  Only immunosuppressive therapy consisting of clinically 
applicable protocols that warrant islet survival and avoid increased morbidity to the recipients, 
should be considered. 
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PRECLINICAL STUDIES: ADVANCES IN ENCAPSULATED ISLET/DEVICE 
TRANSPLANTATION AS A TREATMENT FOR DIABETES 
Jonathan RT Lakey 
Department of Surgery and Biomedical Engineering; Clinical Islet Program, University of 
California Irvine, USA 
Islet transplantation to treat type 1 diabetes has achieved great improvements, as more 
recipients are able to achieve insulin-independence for longer periods of time. Unfortunately, 
the lack of donor organs and immunosuppressive medication regimens continue to impede 
further progress in cell-replacement therapy. Encapsulation of islets for transplantation 
provides a solution to these problems. Cell encapsulation envelopes cells in a biocompatible 
matrix that provides a gradient which allows the diffusion of oxygen and nutrients but 
prevents large immune molecules from reaching the cell, avoiding a host immune response. 
Encapsulation has been suggested since the 1930’s but noteworthy achievements have 
occurred over the last decade. This lecture aims to provide a review including a historical 
background, current research, and future applications of cell encapsulation for the treatment 
of type 1 diabetes.  
Nano-encapsulation has been used to improve diffusion parameters and better islet 
insulin response. Polyethylene glycol (PEG) is one of the most common materials used in 
nano-encapsulation devices as it can crosslink under ultraviolet or visible light exposure 
without threatening cell viability. Nevertheless, the shortcomings of PEG include the lack of 
biocompatibility with the transplant recipient and inadequate protection of islets from 
cytokines. However, by using multi-layer PEGylation and immunosuppressive drug cocktails, 
islets have demonstrated increased stability and longer survival time while minimizing the 
immune response, as indicated by the reduction in human serum albumin, fibronectin, and 
IgG. 
Both synthetic agents, from polyethylene oxide to polyvinyl alcohol, and naturally-
occurring hydrogels, like gelatin, chitosan, and alginate, have been utilized in encapsulation 
engineering and in extracellular matrixes. Though polyglycolic and lactic acid polymers are 
some of the more popular synthetic agents in medical devices, they still pose the risk of 
increased fibrosis and loss of the encased cells. Nevertheless, synthetic biomaterials are still 
being frequently used, with PEG being the most widely used synthetic biomaterial for islet 
encapsulation, though different encapsulation strategies have varying levels of success. 
Such strategies include assembling a thin layered PEG-lipid structure around the surface of 
islets and assembling a multilayer film around islets using biotin and streptavidin.  
Due to the complications with islet encapsulation using synthetic materials, alginate 
encapsulation has risen in popularity due to its improved biocompatibility and stability, easy 
gelation process, and relatively low cost. Alginate has typically been the most popular 
microencapsulation material, due to its widespread availability and ease of production, 
although alginate endotoxin content and purity can vary from different manufacturers. The 
variation in alginate production and purification, in addition to the lack of research regarding 
the optimal transplantation site of islets and optimal donor strain and age, currently stand in 
the way of consistent success in transplanting alginate-encapsulated islets into humans. In 
an effort to improve capsule permeability and mechanical strength, studies have used 
polycations and anions in the encapsulation process, although it often results in a greater 
host biologic response to the transplant. 
 
PRECLINICAL STUDIES: PROPOSED CLINICAL TRIALS OF CORNEA AND PANCREATIC 
ISLET XENOTRANSPLANTATION 
Chung-Gyu Park1,2,3,4,5,6, Kim Kwang-Won7, Byoung-Joon Kim7, Jun-Seop Shin1,2,3,5, 
Chang Ho Yoon1,8,9, Mee Kum Kim1,8,9 
1. Xenotransplantation Research Center, Seoul, Korea 
2. Institute of Endemic Diseases, Seoul, Korea 
3. Cancer Research Institute, Seoul, Korea 
4. Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea 
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5. Department of Microbiology and Immunology, Seoul National University College of 
Medicine, Seoul, Korea 
6. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, 
Korea 
7. Division of Endocrinology, Department of Internal Medicine, Gachon University School of 
Medicine, Incheon 21565, Korea 
8. Laboratory Of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye 
Center, Seoul National University Hospital Biomedical Research Institute, Seoul, Korea 
9. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, 
Korea 
INTRODUCTION: Xenotransplantation using fresh porcine corneas has been suggested as a 
feasible alternative to overcome the shortage of human donor corneas. Porcine islet is also 
considered the best alternative for allogeneic human islets to treat the selected type 1 
diabetes patients with severe hypoglycemic unawareness and glycemic liability despite 
conventional insulin therapy. In this announcement, we discuss preparations of clinical trial 
protocols to conduct the first corneal and islets xenotransplants. To ensure safe and 
transparent clinical trials, all related procedures were standardized based on the international 
consensus established by IXA and WHO. 
DISCUSSION: Regarding corneal xenotransplantation, detailed contents of the protocol have 
been modified with reference to comments provided by ophthalmologists and multidisciplinary 
experts, including an infection specialist, an organ transplantation specialist, a clinical 
pharmacologist, a neuropsychiatrist, a laboratory medicine doctor, and a microbiologist. Two 
patients with bilateral legal corneal blindness (best-corrected visual acuity ≤20/200 in the 
better eye and ≤20/1000 in the candidate eye) will be enrolled. During the screening period, 
participants and their close contacts will have two separate deliberation periods before 
signing informed consent forms. Each patient will undergo corneal xenotransplantation using 
fresh cornea from Seoul National University (SNU) miniature pigs. Commercially available 
immunosuppressants will be administered, and systemic infection prophylaxis will be 
performed according to the program schedule. Data and safety monitoring board (DSMB) is 
independently organized and will monitor the protocol adherence, patient eligibility, intensity 
of follow-up, and regular review of the data. After transplantation, each patient will be 
monitored at a specialized clinic to investigate safety up to 2 years and efficacy up to 1 year. 
For islet xenotransplantation, two type 1 diabetes patients who meet selection and 
exclusion criteria will be enrolled. Primary purpose of this pilot trial is to confirm the safety of 
porcine islets. Porcine islets will be isolated from SNU miniature pig and manufactured in a 
GMP-compliant facility and prepared to meet IXA islet product release criteria including 
sterility, potency, and viability. Clinically applicable immunosuppression regimen modified 
from the one which has been developed from pre-clinical studies in nonhuman primates will 
be administered to warrant the safety of the patients. Independent DSMB will examine the 
protocol adherence, patient eligibility, follow-up schedule, and resulting data. After 
transplantation, two patients will be monitored to investigate the safety of porcine islets up to 
2 years and then followed by life-long surveillance according to the law that will be supposed 
to be implemented by Korean government. 
CONCLUSION AND/OR RECOMMENDATIONS: Detailed clinical trial protocols for the first 
corneal and islet xenotransplants reflecting the global guidelines are provided. For a safe and 
transparent clinical trial, all procedures must be standardized and clinical trial protocols 
should be prepared. 
 
PRECLINICAL STUDIES: HEPATOCYTES XENOTRANSPLANTATION 
Leo H. Buhler 
University Hospitals Geneva, Geneva, Switzerland 
INTRODUCTION: The treatment of acute liver failure is based on optimal supportive medical 
care and, in the most severe cases, liver transplantation. The latter option represents the 
only treatment available in cases of end-stage liver failure. The shortage of organ donors 
limits its application, and the post-transplant care includes lifelong immunosuppressive 
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therapy. Thus, the development of alternative therapies is crucial to bring new therapeutic 
strategies to the clinic.  
Hepatocyte allotransplantation has been proposed for temporary liver function 
support, while the injured liver regenerates, or while waiting for transplantation. As 
hepatocyte allotransplantation is also facing organ shortage, only marginal livers are directed 
to this approach, and the quality of isolated cells is limited. Therefore, the use of xenogeneic 
liver cells has been proposed using encapsulation methods to immunoisolate the implanted 
cells, thus avoiding post-transplant immunosuppression. The choice of using the peritoneum 
as implantation site allows the implantation of significantly higher volumes of cells, compared 
to intra-hepatic implantation. 
We have therefore developed techniques for isolation of large volumes of porcine 
hepatocytes, obtained from freshly procured livers and microencapsulated these cells with 
new types of polymers based on polyethylene glycol-alginate. In a pig-to-nonhuman primate 
transplantation model, the encapsulated porcine hepatocytes were transplanted into baboons 
with acute liver failure induced by 75% liver resection and warm ischemia of the remaining 
liver segment. Fulminant liver failure was characterized by typical modification of liver 
biochemical parameters, severe steatosis, and massive hepatocyte necrosis within the first 
10 days. Hepatocytes from miniature swine were microencapsulated in alginate-based 
microspheres, and transplanted intraperitoneally immediately after liver injury. We could 
show that microencapsulated porcine hepatocytes provide temporary liver function support in 
baboons with fulminant liver failure. 
DISCUSSION: To bring this approach to clinical application, we are working on the 
establishment of a clean pig facility, a GMP-grade laboratory space, and plan to repeat the 
pig-to-nonhuman primate study with higher numbers of animals. We also aim to improve the 
viability and function of the isolated and encapsulated hepatocytes by co-transplanting 
mesenchymal stromal cells with the hepatocytes. We have contacted the Swiss Federal 
Regulatory Agency for Drug Administration, Swissmedic, to establish a road map for initiation 
of a clinical trial. 
CONCLUSION AND/OR RECOMMENDATIONS: A clinical trial of porcine hepatocyte 
transplantation in patients with acute liver failure could be initiated in centers where human 
organ donors are not easily available on an emergency basis. The ethical and regulatory 
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GENETICALLY MODIFIED DONOR PIGS FOR XENOTRANSPLANTATION – STATE OF 
THE ART 
Eckhard Wolf1, Bruno Reichart2 
1Gene Center and 2Walter-Brendel Center for Experimental Medicine, LMU Munich, Munich, 
Germany 
INTRODUCTION: The use of pigs as source of cells, tissues and organs for 
xenotransplantation offers the unique opportunity of genetic engineering the donor animals. 
Gen(om)e editing is speeding progress in this field. More than 40 different genetic 
modifications have been introduced into pigs to prevent immune rejection of xenografts, 
overcome physiological incompatibilities, and reduce the risk of transmitting zoonotic 
pathogens. Genetic modifications to overcome hyperacute and acute vascular rejection of 
pig-to-primate xenografts include the inactivation of the α-1,3-galactosyltransferase (GGTA1) 
gene to eliminate the major xeno-antigen galactose-α1,3-galactose (αGal). Other prominent 
xeno-antigens, i.e. N-acetylneuraminic acid (Neu5Gc) and an Sd(a)-like glycan, have been 
eliminated by inactivating the genes encoding cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase (CMAH) and β-1,4-N-acetyl-galactosaminyl transferase 2 (B4GALNT2). 
A complementary approach is transgenic expression of human complement-
regulatory proteins, such as CD46, CD55 and CD59, singly or in combination. Porcine cells 
and tissues with lacking or reduced swine leukocyte antigens (SLA) should elicit only weak 
responses from the nonhuman primate/human immune system: MHC class I deficient pigs 
have been reported and these show reduced levels of CD4- CD8+ T cells in the peripheral 
blood, but appeared healthy and developed normally. Dysregulation of coagulation and 
disordered haemostasis are frequent complications in preclinical pig-to-nonhuman primate 
xenotransplantation. Key endothelial anticoagulant/antithrombotic proteins that have been 
modified/supplemented by genetic engineering of donor pigs include human thrombomodulin 
(THBD), endothelial protein C receptor (EPCR), tissue factor pathway inhibitor (TFPI), and 
ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1 alias CD39). In addition, 
transgenic pigs that express anti-apoptotic and anti-inflammatory proteins, such as human 
tumour necrosis factor-alpha-induced protein 3 (A20) and human heme oxygenase-1 (HO-1) 
have been produced. 
Transgenic strategies to overcome cellular rejection of pig-to-primate xenografts 
include the expression of CTLA4-Ig or LEA29Y (to block co-stimulation of T cells), of HLA-
E/beta2-microglobulin (to protect porcine cells against human NK-cell mediated cytotoxicity), 
and of human CD47 (to suppress phagocytic activity of monocytes/macrophages). Aberrant 
phagocytosis of human platelets during perfusion of porcine livers could be partially 
overcome by deleting the porcine asialoglycoprotein receptor (ASGR). 
Genetic modifications which decrease the risk for porcine endogenous retrovirus 
infections include the long-term reduction of PERV expression via PERV-specific siRNAs and 
CRISPR/Cas9 mediated inactivation of PERV proviruses by mutating their pol genes. 
DISCUSSION: The combination of genetic modifications required may depend on the type of 
organ/tissue and – especially for cellular xenografts – the transplantation site. Cellular 
localisation and level of transgene expression are critical for the functionality and potential 
side effects of specific modifications. Segregation of independent integration sites is avoided 
by “combineering” and “gene stacking”, i.e., random or targeted placement of multiple 
expression cassettes in a single genomic locus. 
CONCLUSION AND/OR RECOMMENDATIONS: Technical advances in the generation of 
genetically multi-modified pigs and new developments in the field of immunosuppression led 
to significant progresses in many areas of xenotransplantation, including pancreatic islets, 
but also vascularised organs like kidneys, hearts and lungs. Xenotransplantations can thus 
be considered as realistic future therapeutic options together with regenerative medicine 




PIGS AS A XENOGRAFT SOURCE ANIMAL AND BIOSECURITY IN SOUTH KOREA 
Curie Ahn 
Division of Nephrology, College of Medicine, Seoul National University, Seoul, South-Korea 
INTRODUCTION: For the treatment of incurable diseases, transplantation has been 
performed during the past several decades. However, there has been a severe shortage of 
transplantable organs, so that xenotransplantation research has been conducted using 
alternatives. Miniature pigs might be the suitable model of organ donor for 
xenotransplantation because of their physio-anatomical similarity to humans. In 
xenotransplantation research, immunological rejections and infections such as PERV, PLHV, 
PCMV, and other xenozoonosis infections are major barriers that need to be overcome for 
successful xenotransplantation. Microbiological safety is an important issue in pigs used as 
xenograft source. “The International Xenotransplantation Association consensus statement 
on conditions for undertaking clinical trials of porcine islet production in type I diabetes” was 
announced, and it contained some criteria such as designated pathogen list and standard 
operation procedures for source animal production. To establish a biosecure condition, all 
steps such as quarantine, rederivation, microbiological screening, veterinary care, individual 
data for medication, should be strictly controlled. Recently, several biosecure pig facilities for 
xenograft were successfully launched and maintained in South Korea. Especially, new 
infrastructure for xenotransplantation research, named designed animal resource center 
(DARC), started operation from 2014, and it has the capacity for 150 pigs and 200 nonhuman 
primates. 
 
BARRIER FACILITIES FOR DPF SOURCE PIGS: CHINA EXPERIENCE 
Wang Wei 
The Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital of Central-
South University; Changsha, China 
INTRODUCTION: Paragraph 2 of the Changsha Communiqué (2008) states “Animals used in 
xenotransplantation should be from a closed herd bred for the purpose and housed in a well-
controlled, pathogen-free environment with high standards of animal welfare. Source animals 
should be extensively tested to ensure freedom from known pathogens with appropriate 
biosecurity and surveillance in place to ensure continued freedom from infectious disease.” 
The consensus statement published in 2009 by IXA provided guidance about barrier facility 
and Designed pathogen free pig. 
We collected more than 10,000 samples from 11 Chinese local closed pig breeds [1], and 
found a pig specimen with PERV-C gene deficiency in 2002. By inbreeding 22 generations, 
we established stable and closed herd inbred pigs with high islet yields and we named it 
Xeno-1. Genomic analyses and experiments revealed that Xeno-1 is natural PERV-C free pig 
which could greatly reduce the potential risk of cross-species transmission of PERVs. 
We established standards on Medical grade DPF donor pig for xenotransplantation, including 
genetic standard, microbiological surveillance, formula feeds, regulation for pathological 
diagnosis, requirements of environment and housing facilities, and a list of designated 
pathogens to be excluded from the source herd based on consensus statement published in 
2009 by IXA [2]. We established a GMP barrier facility for DPF source pig in Changsha, China 
in 2012. This facility is inspected and approved by the third-party authorities, including 
National Institutes for Food and Drug Control, State Key laboratory of Virology, and CDC of 
Hunan Province. We verified the bio-safety of DPF source pig in humanised mouse model 
and nonhuman primate model. Approved by the government, we conducted a clinical trial with 
Type 1 diabetes patients under the regulatory framework for xenotransplantation. After 5 
years follow-up, no PERV transmission was found in the patients and their wives. In addition, 
we also confirmed that no microchimerism happened.  
DISCUSSION AND CONCLUSION: Source pigs used in xenotransplantation should have a 
clear and stable genetic background, so as to ensure they always be PERV-C negative and 
easy to breed under barrier facility. Pig with unstable genetic background is easy to be infertile 
under barrier facility. Well trained staff, strict and operational SOP, accurate and rigorous data 
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retention, are all important for the operation in GMP barrier facility for DPF source pig. GMP 
barrier facility and DPF source pig should be under bio-safety surveillance by authorized third 
party. The bio-safety of DPF source pig must be verified and confirmed by biological tests. 
RECOMMENDATIONS: DPF source pig need GMP barrier facility, SOP, regulation and bio-
safety surveillance by the third-party authorized lab. Source pigs used in xenotransplantation 
should have a clear and stable genetic background. Develop a list of pathogens to be 
excluded from the source pig according to local state/region guidelines. 
1. Xing X, Xu S, Mo Z, et al. Analysis of subtypes of porcine endogenous retrovirus in 
hybrids of Landrace with Qinghai Bamei swine. Chinese Journal of Zoonoses, 
2007,23(9):878-882 
2. Schuurman HJ. The International Xenotransplantation Association consensus statement 
on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--
chapter 2: Source pigs. Xenotransplantation. 2009;16:215-222. 
 
BARRIER FACILITIES: USA 
Agnes Azimzadeh 
Department of Surgery, Massachusetts General Hospital and Harvard Medical School, 
Boston, MA, USA 
INTRODUCTION: Xenotransplantation of porcine cells, tissues, and organs is associated 
with the potential transmission of porcine microorganisms to the human recipient. Several 
groups of experts throughout the world have reviewed potential infectious risks associated 
with xenotransplantation. The World Health Assembly was consulted in 2004 and several 
consultations with the World Health Organization (Geneva 1997, Changsha 2008, Geneva 
2011) provided guidance documents. The IXA published several consensus statements for 
future clinical trials of xenotransplantation. In parallel to those efforts, the U.S. Department of 
Health and Human Services (DHHS) published a Public Health Service (PHS) Guideline on 
Infectious Disease Issues in Xenotransplantation to address the infectious disease concerns 
raised by xenotransplantation. The Guideline was developed within DHHS by the Center for 
Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Health 
Resources and Services Administration (HRSA), National Institutes of Health (NIH), and the 
Assistant Secretary for Planning and Evaluation. Published general principles provided 
guidance on the development, design, and implementation of clinical protocols for potential 
sponsors and local review bodies of xenotransplantation clinical trials, in preparing 
submissions to FDA or the Secretary’s Advisory Committee on Xenotransplantation (SACX). 
Clinical trials conducted within the United States are subject to regulation by the FDA. FDA 
has published a guidance document (“Guidance for Industry: Precautionary Measures to 
Reduce the Possible Risk of Transmission of Zoonoses by Blood and Blood Products from 
Xenotransplantation Product Recipients and Their Contacts”) (2003). All these documents 
provided a basis for the production of safe donor pigs for xenotransplantation. The PHS 
Guideline acknowledges the complexity of infectious disease issues and recommends 
ongoing discussions of scientific and medical issues raised by xenotransplantation. 
Accordingly, recent progress in the field with respect to understanding risks by PERV 
and other pathogens, advancement of diagnostic capabilities and modifications of the pig 
genome using CRISPR-Cas9 technology, have increased the relevance for further 
reconsideration of potential infectious risks in xenotransplantation. A “barrier facility” by 
definition is highly biosecure and is recommended by guidance. A recent report described the 
development of a Source Animal (barrier) Facility (SAF) established in the U.S. for 
generating designated pathogen-free (DPF) pigs to serve as donors of viable organs, tissues, 
or cells for xenotransplantation into clinical patients. Another facility has been designed and 
is awaiting imminent construction. Such facility allows for pathogen elimination and 
prevention within a regulated DPF closed pig herd and for long-term breeding and production 
of xenotransplantation materials. Specific techniques involve caesarian derivation, colostrum 
deprivation, sows of specified pathogen-free (SPF) health status, and equipment sterilization 
protocols. To reduce the risk of prion-based diseases, feed components should be traceable 
and free of cattle-derived materials for multiple generations prior to donation. The operations 
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in such a SAF should be according to current Good Manufacturing Practices (cGMP) 
conditions. It is also proposed that SAF animal husbandry conditions should follow those for 
research animals per the Guide for the Care and Use of Laboratory Animals with research 
facility registration and accreditation by the United States Department of Agriculture (USDA, 
in the USA), the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) respectively, and conduct of experiments under oversight of an 
Institutional Animal Care and Use Committee (IACUC). 
 
XENOTRANSPLANTATION – PREVENTING ASSOCIATED INFECTIOUS RISK:  
A WHO CONSULTATION PART II 
Linda Scobie 
Department of Biological and Biomedical Sciences, School of Health and Life Sciences, 
Glasgow 
Caledonian University, Glasgow, Scotland, U.K. 
INTRODUCTION:  In 2011, the second global Consultation on Regulatory Requirements for 
Xenotransplantation clinical trials was held in Geneva, Switzerland. As a result of this meeting, 
the manuscript “Xenotransplantation-associated infectious risk: a WHO consultation” was 
published in Xenotransplantation in 2012 [1]. The document summarised the approaches to 
disease surveillance in individual recipients of non-human tissues and described some 
general concepts. At this point, progress to the clinic was still slow and consensus guidelines 
and recommendations didn’t always provide clear information on how to proceed. In August 
2018, Xenotransplantation published a special issue on safety and state of the art prevention 
of transmission of porcine viruses. In addition, the FDA has updated their Guideline on Source 
Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation 
Products in Humans [2] as have the original consensus statements put forward by IXA [3,4].  
In support, there have been many publications looking at sensitive assays [5] and approaches 
for comprehensive pathogen testing [6]. Indeed, some recent literature suggests promise for 
the deletion of PERV elements in pigs, if this is required [7].  The field has clearly moved 
forward, and as such, we are now in a position to progress to the clinic as we have much more 
safety data available to answer some of the previous questions posed and guideline 
recommendations. 
The aim of the previous meeting was to bring harmonisation of global practices of 
Xenotransplantation, however we still do not have fully evaluated commercial assays for 
certain pathogens. In addition, the global inventory of xenotransplantation doesn’t appear to 
have been updated since 2015 http://www.humanxenotransplant.org/home/ possibly due to a 
lack of awareness from individuals proposing trials. Questions are still being asked as to the 
relevance of PERV as a pathogen and what the risk would be with regard to unknown 
elements not detected in the initial screening of both animal and product.  These are difficult 
to answer; in essence, to fully evaluate the microbiological risk, clinical trials are needed. 
3. Fishman, J.A., L. Scobie, and Y. Takeuchi, Xenotransplantation-associated infectious 
risk: a WHO consultation. Xenotransplantation, 2012. 19(2): p. 72-81. 
4. Food and Drug Administration. Guidance for industry: source animal, product, preclinical, 
and clinical issues concerning the use of xenotransplantation products in humans. 2003, 
updated 2016. 
https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinf
ormation/guidances/xenotransplantation/ucm533036.pdf. Accessed June 13, 2017. 2016. 
5. Spizzo, T., et al., First update of the International Xenotransplantation Association 
consensus statement on conditions for undertaking clinical trials of porcine islet products 
in type 1 diabetes--Chapter 2a: source pigs--preventing xenozoonoses. 
Xenotransplantation, 2016.23(1): p. 25-31. 
6. Denner, J., et al., First update of the International Xenotransplantation Association 
consensus statement on conditions for undertaking clinical trials of porcine islet products 
in type 1 diabetes--Chapter 5: recipient monitoring and response plan for preventing 
disease transmission. Xenotransplantation, 2016. 23(1): p. 53-9. 
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7. Denner, J., Sensitive methods and improved screening strategies are needed for the 
detection of pig viruses. Xenotransplantation, 2017.24(3). 
8. Gazda, L.S., et al., A comprehensive microbiological safety approach for agarose 
encapsulated porcine islets intended for clinical trials. Xenotransplantation, 2016. 23(6): 
p. 444-463. 
9. Niu, D., et al., Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. 




SESSION IV - The regulatory environment for xenotransplantation clinical trials 
 
FDA CONSIDERATIONS ON THE INITIATION OF XENOTRANSPLANTATION CLINICAL 
TRIALS 
Judith Arcidiacono 
U.S. Food and Drug Administration 
INTRODUCTION: The development of U.S. policy on xenotransplantation as a means to 
circumvent the shortage of human organs for transplantation into humans began around 25 
years ago and continues to evolve as new technologies bring possibility of 
xenotransplantation closer to the clinic. In 2016, the FDA Center for Biologics Evaluation and 
Research (CBER) published a revision to the 2003 “Guidance for Industry: Source Animals, 
Product, Preclinical and Clinical Issues Concerning the Use of Xenotransplantation Products 
in Humans”. The primary focus of the update was to include FDA guidance documents 
applicable to xenotransplantation that did not exist in 2003. Currently, the FDA Center for 
Veterinary Medicine (CVM) is finalizing the “Draft Guidance for Industry: Regulation of 
Intentionally Altered Genomic DNA in Animals”. This guidance document is applicable to 
xenotransplantation products that utilize “animals whose genomes have been intentionally 
altered to produce xenotransplantation products” and outlines regulatory requirements for the 
intentionally altered genomic DNA in such animals. The regulatory approaches utilized by 
both CBER and CVM are focused on reducing the potential risks for use of 
xenotransplantation products. 
DISCUSSION: Transmission of known and unknown pathogens to recipients of 
xenotransplantation products is one of the primary concerns when initiating first-in-human 
(FIH) xenotransplantation clinical trials. A product development program for 
xenotransplantation products begins with the establishment of a closed source herd that has 
been adequately tested for adventitious agents. Programs for monitoring animal health and 
animal husbandry should focus on excluding infectious diseases from the pool of organ/cell 
donor animals. Molecular characterization of source animals that have been genetically 
altered should be conducted and include genotypic and phenotypic analyses. 
The product development program also includes establishing protocols for the harvest 
of cells, tissues and/or organs from the animal and transportation to the clinical site/surgical 
suite. Procedures should be carried out in a facility that prevents the introduction of infectious 
agents. As with other biologics regulated by FDA, the xenotransplantation product must meet 
lot release criteria that includes identity, potency (or activity), and safety (e.g., microbiological 
sterility). 
Prior to the initiation of FIH clinical trials, proof of concept and safety studies utilizing 
an appropriate animal model of disease should be conducted.  Many factors should be taken 
into consideration in such studies, including the selection of an appropriate animal model, 
use of the intended clinical product, the immunosuppression regimen, the use of an immuno-
isolatory device (e.g., encapsulation) when appropriate, and the need for re-implantation. 
For the U.S. FDA, decisions to permit FIH clinical trials are based on established 
regulatory principles for cell therapy products. Clinical protocols should take into account the 
potential for prolonged biological activity and associated safety requirements. Recommended 
clinical follow-up for xenotransplantation products is 50 years. In addition to safety, a range of 
clinical and pharmacodynamic endpoints should be collected to inform the design of later 
clinical trials. 
CONCLUSION AND/OR RECOMMENDATIONS: An appropriate risk/benefit profile for each 
xeno product must be defined prior to initiating clinical trials. The use of best practices and 
validated technologies as well as vigilant disease monitoring can reduce the risk of zoonotic 
infections. Appropriate record keeping and archiving of animal and patient samples also 






MONITORING AND CONTROL OF VIRAL INFECTIONS IN XENOTRANSPLANTATION 
RECIPIENTS 
Minhua Luo 
State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences 
INTRODUCTION: Solid organ or cell transplantation is the most efficient way to treat patients 
with terminal organ failure. However, lack or limited organs have hampered the treatment, 
and pancreas is in an extremely desperate wanted status. Because of the limited resource of 
organs, long waiting lists and severe status of patients, plus the incomplete screening of 
pathogens, lethal infections happen as reported in 2003 and 2005. Two LCMV infected 
donors did not show clear infectious symptoms, and their organs were transplanted to 
several recipients who demonstrated severe infectious disease. These cases released two 
important messages: limited donor (donor issue) and risk of infection (safety issue). 
DISCUSSION AND CONCLUSION: (1) Solution for donor issues; xenotransplantation and/or 
stem cell transplantation: (2) Safety issues; biosafety, virus infection, screening and 
monitoring virus infection  
RECOMMENDATIONS: (1) Screening potential viruses from the donor (piglet) to make sure 
it is virus infection risk free: (2) check the infection or infection status in the potential 
recipients: (3) monitoring the virus infection in the recipients (the infection can from 
endogenous latent pathogens, acquired from the community, or the donor). 
 
EU GUIDELINES AND POLICY TO UNDERTAKE CLINICAL TRIALS 
Ralf Reinhard Tönjes 
Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, Division of 
Medical Biotechnology, Section 6/4 Non-vital Tissue Preparations and Xenogeneic Cell-
Therapeutics, Langen, Germany 
INTRODUCTION: Since 2004, clinical trials of medicinal products have to be approved in 
Europe. Authorization of clinical trials is necessary in addition to the favorable opinion of the 
concerned ethics committee. This procedure has undoubtedly resulted in larger expenditures 
with respect to time and costs of planning and conducting of clinical trials. However, the 
implementation of Good Clinical Practice has increased both safety for the trial subjects and 
validity of the data. 
In 2014, the European Parliament and Council adopted the new Clinical Trial 
Regulation (EU) No 536/2014, with the hope of increasing the number of clinical trials 
conducted in the EU. Most likely in 2020, the Regulation will replace the current European 
Clinical Trial Directive 2001/20/EC. It offers new principles and provisions that aim to 
counteract the limitations of working with the Directive, promote better harmonization and 
increase transparency in the reporting of clinical trial results. The assessment of a clinical 
trial application (CTA) will proceed through a twofold procedure based on defined timelines, 
with the Reporting Member State coordinating the assessment of the scientific features of the 
trial (part 1), and each Concerned Member State carrying out a separate assessment 
covering national features (part 2). In Germany, the National Competent Authorities (NCA) 
Bundesinstitut für Arzneimittel und Medizinprodukte(BfArM, Federal Institute for Drugs and 
Medical Devices) and Paul-Ehrlich-Institut (PEI, Federal Institute for Vaccines and 
Biomedicines) are responsible. 
For advanced therapies, the same basic principles for assessment apply as for any 
other biotechnological medicinal product. Nevertheless, the extent of data for quality, safety, 
and efficacy may be highly specific. Since 2007, advanced therapy medicinal products 
(ATMP) including gene therapy medicinal products, somatic cell therapy medicinal products 
as well as tissue-engineered products, are uniformly regulated across Europe. According to 
Regulation (EC) No 1394/2007 tissue engineered products may contain cells or tissues of 
human or animal origin, or both. The cells or tissues may be viable or non-viable. It may also 
contain additional substances, such as cellular products, biomolecules, biomaterials, 
chemical substances, scaffolds or matrices. However, products containing or consisting 
exclusively of non-viable human or animal cells and/or tissues, which do not contain any 
viable cells or tissues and which do not act principally by pharmacological, immunological or 
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metabolic action, are excluded from this definition. The Committee for Advanced Therapies 
(CAT) at the European Medicines Agency (EMA) has been established to meet the scientific 
and regulatory challenges with advanced therapies. The CAT plays a central role in the 
regulatory process. 
DISCUSSION: The legislative framework, definitions, the procedures for submitting a clinical 
trial application (CTA) and an overview on the regulatory requirements for clinical trials will be 
provided. 
CONCLUSION AND/OR RECOMMENDATIONS: Xenogeneic cell therapy is regulated as a 
cell-based medicinal product, for which regulations and directives exist. So far, no 
xenogeneic cell therapy product has achieved regulatory approval in Europe. In the long run, 
when the results of pig organ xenotransplantation in nonhuman primates suggest a realistic 





SESSION V - The role of IXA and WHO in the regulation of xenotransplantation 
 
 
SUMMARY OF RECENT IXA-FDA MEETINGS [BOSTON 2016; BALTIMORE 2017]  
ROLE OF THE IXA ETHICS COMMITTEE 
Richard N. Pierson III 
Massachusetts General Hospital; Harvard Medical School 
ABSTRACT: Since 2015, the IXA has proactively engaged the US Food and Drug 
Administration (FDA) to consult regarding how new developments in the field of 
xenotransplantation may affect design, conduct, and regulatory oversight of clinical 
xenotransplantation trials.  As reported recently in Xenotransplantation (1), IXA Council 
members and FDA representatives met informally at the 2016 American Transplant Congress 
meeting. Consequently, FDA and IXA jointly organized a public symposium preceding the 
IXA 2017 Congress. Improving preclinical organ and cell xenotransplantation outcomes were 
discussed in the context of previously published preclinical benchmarks.  Advances in gene 
editing technology have enabled rapid generation of a huge variety of changes to the pig.  
Some combination of gene modifications to reduce immunogenicity and/or address species-
specific molecular incompatibilities may simplify the immunosuppressive regimen needed to 
prevent innate and adaptive immune injury, and facilitate clinical translation of organ, tissue, 
or cell xenografts. The infectious risks associated with allo- and xeno-transplantation were 
compared, along with how xenozoonoses might be diagnosed and managed, should they 
occur. Current definitions of what constitutes a “clean” donor pig, diagnosis of unknowns 
pathogens, long-term archiving, and risk management for experimental subjects and their 
close contacts were discussed. Existing assays appear sensitive to diagnose known and 
unknown infectious risks; therapies likely to effectively treat infections by known organisms 
are available; and, ultimately, infectious safety risk can only be determined in clinical trials.  
The consensus was expressed that progress in the field has rendered the risk/benefit ratio 
more favorable for both the individual study subject and for society. 
FDA presented the 2016 update of their guidance document “Source Animal, Product, 
Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in 
Humans”.  FDA emphasized the role of balanced risk assessment, and a “layered” approach 
to optimizing subject safety, including application of best practices and ongoing process 
validation, as well as the importance of measuring ‘activity’ of the ‘product’ (therapeutic 
effectiveness), and predicting consistent performance. Preclinical “proof-of-concept” data 
recommendations, the possible role of initial safety or dose escalation studies, and the need 
for contemporaneous or historical reference groups (‘controls’) were discussed. 
In the general discussion, while emphasizing that every proposal must be considered 
individually, consensus was explored regarding results that IXA and FDA might consider 
‘sufficient’ to justify proposing a clinical organ xenograft trial in various scenarios.  FDA 
indicated that a multigene pig and experimental treatment regimens (involving agents not-yet-
approved for other uses in humans) could be considered within a single application. FDA 
strongly encouraged regular exchange of information and dissemination of regulatory best 
practices, in support of a shared FDA-IXA goal: advancing and protecting public health 
through the development of safe, effective xenotransplantation products. 
Working in concert with TTS and in relationship with WHO, IXA’s mission is to 1) 
foster the science of xenotransplantation; 2) educate health care providers and lay persons; 
and 3) guide the development of scientifically sound, internationally consistent public policy.  
Advisory to the IXA Council, the IXA Ethics Committee promotes evidence-based ethical 
guidelines for xenotransplantation clinical trials for consideration by national regulatory 
authorities, trial proposers and sponsors, and any other concerned parties. 
1. Cooper DKC, Cowan P, Fishman JA, Hering BJ, Mohiuddin MM, Pierson RN 3rd, Sachs 
DH, Schuurman H-J, Tector JA, Tönjes RR. Joint FDA-IXA Symposium, September 20, 





SESSION VI - Review of Changsha Communiqué Principles and Guidance 
 
RECOMMENDATIONS OF THE 2nd WHO GLOBAL CONSULATION (GENEVA 2011) –  
HOW HAVE WE MOVED ON 
Emanuele Cozzi 
Transplant Immunology Unit, Padua University Hospital, Padua, Italy 
INTRODUCTION. In January 2011, the Second WHO International Consultation on 
Regulatory Requirements for Xenotransplantation Clinical Trials took place at WHO 
headquarters in Geneva, Switzerland. The objectives of such a Consultation were to review 
the current status of xenotransplantation science and practice; to determine whether updates 
to the Changsha Communiqué's guidance to WHO, Member State health regulatory 
authorities, and study investigators and/or sponsors of xenotransplantation trials were 
required; and to discuss and refine draft guidance for infectious disease surveillance, 
prevention, and response appropriate to support various probable clinical 
xenotransplantation trial scenarios. 
At the conclusion of the consultation, participants recommended to WHO to facilitate 
global collaboration for laboratory investigations; to encourage transparency in 
xenotransplantation related activities; and to convene regular global consultations on 
xenotransplantation activities. Important recommendations were also issued to the attention 
of Member States, investigators, proposers, or study sponsors. In particular, it was 
recommended that such parties should seek global consistency in requirements for clinical 
trials by referring to best global standards and experts’ advice for issues regarding source 
donor animals; recipients, family members and close contacts surveillance using state-of-the-
art diagnostic methodology; risk/benefit analysis; and trial infrastructure. Furthermore, it was 
also recommended that stakeholders should combat unfounded assertions on human 
xenotransplantation; and to refer to experienced independent laboratories. 
At this stage, it is undisputable that a refinement or integration of existing regulatory 
instruments to allow improved xenotransplantation practices has taken place recently or is 
underway in many countries. Indeed, important regulatory changes have occurred or are in 
progress in several geographic areas that include Europe, Korea, Japan, and China. Such 
significant changes in the regulatory frameworks encompass the most diverse aspects 
related to the clinical application of xenotransplantation procedures and comprise ethical 
issues, source animals and product specifications, study monitoring, sample archiving, patient 
follow- up, and even insurance coverage in some legislations. 
Together such measures are expected to provide a better care and protection to 
xenograft recipients and their close contacts, but also a higher safety profile to 
xenotransplantation procedures, with an ultimate net gain in terms of international public 
health. In this context, it is undeniable that a continued close collaboration and synergy 
between WHO and IXA will be of paramount importance to allow the development of a safe 
and successful application of clinical xenotransplantation. 
 
